

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representation of
The original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



PDF
Endnote

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : C07D 273/00, 275/00, A61K 31/17</p>	<p>A1</p>	<p>(11) International Publication Number: WO 99/32463 (43) International Publication Date: 1 July 1999 (01.07.99)</p>
<p>(21) International Application Number: PCT/US98/27265 (22) International Filing Date: 22 December 1998 (22.12.98) (30) Priority Data: 08/995,749 22 December 1997 (22.12.97) US (71) Applicant: BAYER CORPORATION [US/US]; 100 Bayer Road, Pittsburgh, PA 15205 (US).</p>	<p>(72) Inventors: MILLER, Scott; 220 Lindenwood Drive, Exton, PA 19341 (US). OSTERHOUT, Martin; 3217 Quiet Mill Road, Raleigh, NC 27612 (US). DUMAS, Jacques; 821 Beechwood Road, Orange, CT 06477 (US). KHIRE, Uday; 101 Tanglewood Drive, Hamden, CT 06518 (US). LOWINGER, Timothy, Bruno; 5-7, #1203 Chitose-cho, Nishinomiya, Hyogo 662-0046 (JP). RIEDL, Bernd; 13 Cedrus Court, Branford, CT 06405 (US). SCOTT, William, J.; 210 Saddle Hill Drive, Guilford, CT 06437 (US). SMITH, Roger, A.; 65 Winterhill Road, Madison, CT 06443 (US). WOOD, Jill, E.; 72 Pickwick Road, Hamden, CT 06517 (US). GUNN, David; 40 Wood Street, Hamden, CT 06517 (US). HATOUM-MOKDAD, Holia; 43 Joseph Lane, Hamden, CT 06514 (US). RODRIGUEZ, Mareli; 281 Durham Road, Guilford, CT 06437 (US). SIBLEY, Robert; 1187 Mt. Carmel Avenue, North Haven, CT 06473 (US). WANG, Ming; 112 Hoyt Street #4F, Stamford, CT 06905 (US). (74) Agents: TRAVERSO, Richard, J. et al.; Millen, White, Zelano & Branigan, P.C., Arlington Courthouse Plaza 1, Suite 1400, 2200 Clarendon Boulevard, Arlington, VA 22201 (US). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published With international search report.</p>	
<p>(54) Title: INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS (57) Abstract This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases and proteolytic enzyme mediated diseases, and pharmaceutical compositions for use in such therapy.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

5

10

Inhibition of p38 Kinase Using Symmetrical and Unsymmetrical Diphenyl Ureas

15

Field of the Invention

This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases and proteolytic enzyme mediated diseases, and pharmaceutical compositions for use in such therapy.

20

Background of the Invention

Two classes of effector molecules which are critical for the progression of rheumatoid arthritis are pro-inflammatory cytokines and tissue degrading proteases. Recently, a family of kinases was described which is instrumental in controlling the transcription and translation of the structural genes coding for these effector molecules.

25

The mitogen-activated protein (MAP) kinase family is made up of a series of structurally related proline-directed serine/threonine kinases which are activated either by growth factors (such as EGF) and phorbol esters (ERK), or by IL-1, TNF α or stress (p38, JNK). The MAP kinases are responsible for the activation of a wide variety of transcription factors and proteins involved in transcriptional control of cytokine production. A pair of novel protein kinases involved in the regulation of cytokine synthesis was recently described by a group from SmithKline Beecham (Lee et al. *Nature* 1994, 372, 739). These enzymes were isolated based on their affinity to bond to a class of compounds, named CSAIDSs (cytokine suppressive anti-inflammatory drugs) by SKB. The CSAIDs, bicyclic pyridinyl imidazoles, have been shown to have cytokine inhibitory activity both
30
35
in *vitro* and *in vivo*. The isolated enzymes, CSBP-1 and -2 (CSAID binding protein 1 and

2) have been cloned and expressed. A murine homologue for CSBP-2, p38, has also been reported (Han et al. *Science* 1994, 265, 808).

Early studies suggested that CSAIDs function by interfering with m-RNA translational events during cytokine biosynthesis. Inhibition of p38 has been shown to inhibit both
5 cytokine production (eg., TNF α , IL-1, IL-6, IL-8) and proteolytic enzyme production (eg., MMP-1, MMP-3) *in vitro* and/or *in vivo*.

Clinical studies have linked TNF α production and/or signaling to a number of diseases
10 including rheumatoid arthritis (Maini. *J. Royal Coll. Physicians London* 1996, 30, 344). In addition, excessive levels of TNF α have been implicated in a wide variety of inflammatory and/or immunomodulatory diseases, including acute rheumatic fever (Yegin et al. *Lancet* 1997, 349, 170), bone resorption (Pacifici et al. *J. Clin. Endocrinol. Metabol.* 1997, 82, 29), postmenopausal osteoporosis (Pacifici et al. *J. Bone Mineral Res.*
15 1996, 11, 1043), sepsis (Blackwell et al. *Br. J. Anaesth.* 1996, 77, 110), gram negative sepsis (Debets et al. *Prog. Clin. Biol. Res.* 1989, 308, 463), septic shock (Tracey et al. *Nature* 1987, 330, 662; Girardin et al. *New England J. Med.* 1988, 319, 397), endotoxic shock (Beutler et al. *Science* 1985, 229, 869; Ashkenasi et al. *Proc. Nat'l. Acad. Sci. USA* 1991, 88, 10535), toxic shock syndrome, (Saha et al. *J. Immunol.* 1996, 157, 3869; Lina
20 et al. *FEMS Immunol. Med. Microbiol.* 1996, 13, 81), systemic inflammatory response syndrome (Anon. *Crit. Care Med.* 1992, 20, 864), inflammatory bowel diseases (Stokkers et al. *J. Inflamm.* 1995-6, 47, 97) including Crohn's disease (van Deventer et al. *Aliment. Pharmacol. Therapeu.* 1996, 10 (Suppl. 2), 107; van Dullemen et al. *Gastroenterology* 1995, 109, 129) and ulcerative colitis (Masuda et al. *J. Clin. Lab.*
25 *Immunol.* 1995, 46, 111), Jarisch-Herxheimer reactions (Fekade et al. *New England J. Med.* 1996, 335, 311), asthma (Amrani et al. *Rev. Malad. Respir.* 1996, 13, 539), adult respiratory distress syndrome (Roten et al. *Am. Rev. Respir. Dis.* 1991, 143, 590; Suter et al. *Am. Rev. Respir. Dis.* 1992, 145, 1016), acute pulmonary fibrotic diseases (Pan et al. *Pathol. Int.* 1996, 46, 91), pulmonary sarcoidosis (Ishioka et al. *Sarcoidosis Vasculitis*
30 *Diffuse Lung Dis.* 1996, 13, 139), allergic respiratory diseases (Casale et al. *Am. J. Respir. Cell Mol. Biol.* 1996, 15, 35), silicosis (Gossart et al. *J. Immunol.* 1996, 156, 1540; Vanhee et al. *Eur. Respir. J.* 1995, 8, 834), coal worker's pneumoconiosis (Borm

- et al. *Am. Rev. Respir. Dis.* 1988, 138, 1589), alveolar injury (Horinouchi et al. *Am. J. Respir. Cell Mol. Biol.* 1996, 14, 1044), hepatic failure (Gantner et al. *J. Pharmacol. Exp. Therap.* 1997, 280, 53), liver disease during acute inflammation (Kim et al. *J. Biol. Chem.* 1997, 272, 1402), severe alcoholic hepatitis (Bird et al. *Ann. Intern. Med.* 1990, 112, 917), malaria (Grau et al. *Immunol. Rev.* 1989, 112, 49; Taverne et al. *Parasitol. Today* 1996, 12, 290) including *Plasmodium falciparum* malaria (Perlmann et al. *Infect. Immunit.* 1997, 65, 116) and cerebral malaria (Rudin et al. *Am. J. Pathol.* 1997, 150, 257), non-insulin-dependent diabetes mellitus (NIDDM; Stephens et al. *J. Biol. Chem.* 1997, 272, 971; Ofei et al. *Diabetes* 1996, 45, 881), congestive heart failure (Doyama et al. *Int. J. Cardiol.* 1996, 54, 217; McMurray et al. *Br. Heart J.* 1991, 66, 356), damage following heart disease (Malkiel et al. *Mol. Med. Today* 1996, 2, 336), atherosclerosis (Parums et al. *J. Pathol.* 1996, 179, A46), Alzheimer's disease (Fagarasan et al. *Brain Res.* 1996, 723, 231; Aisen et al. *Gerontology* 1997, 43, 143), acute encephalitis (Ichiyama et al. *J. Neurol.* 1996, 243, 457), brain injury (Cannon et al. *Crit. Care Med.* 1992, 20, 1414; Hansbrough et al. *Surg. Clin. N. Am.* 1987, 67, 69; Marano et al. *Surg. Gynecol. Obstetr.* 1990, 170, 32), multiple sclerosis (M.S.; Coyle. *Adv. Neuroimmunol.* 1996, 6, 143; Matusevicius et al. *J. Neuroimmunol.* 1996, 66, 115) including demyelination and oligodendrocyte loss in multiple sclerosis (Brosnan et al. *Brain Pathol.* 1996, 6, 243), advanced cancer (MucWiergon et al. *J. Biol. Regulators Homeostatic Agents* 1996, 10, 25), lymphoid malignancies (Levy et al. *Crit. Rev. Immunol.* 1996, 16, 31), pancreatitis (Exley et al. *Gut* 1992, 33, 1126) including systemic complications in acute pancreatitis (McKay et al. *Br. J. Surg.* 1996, 83, 919), impaired wound healing in infection inflammation and cancer (Buck et al. *Am. J. Pathol.* 1996, 149, 195), myelodysplastic syndromes (Raza et al. *Int. J. Hematol.* 1996, 63, 265), systemic lupus erythematosus (Maury et al. *Arthritis Rheum.* 1989, 32, 146), biliary cirrhosis (Miller et al. *Am. J. Gastroenterolog.* 1992, 87, 465), bowel necrosis (Sun et al. *J. Clin. Invest.* 1988, 81, 1328), psoriasis (Christophers. *Austr. J. Dermatol.* 1996, 37, S4), radiation injury (Redlich et al. *J. Immunol.* 1996, 157, 1705), and toxicity following administration of monoclonal antibodies such as OKT3 (Brod et al. *Neurology* 1996, 46, 1633). TNF α levels have also been related to host-versus-graft reactions (Piguet et al. *Immunol. Ser.* 1992, 56, 409) including ischemia reperfusion injury (Colletti et al. *J. Clin. Invest.* 1989,

85, 1333) and allograft rejections including those of the kidney (Maury et al. *J. Exp. Med.* 1987, 166, 1132), liver (Imagawa et al. *Transplantation* 1990, 50, 219), heart (Bolling et al. *Transplantation* 1992, 53, 283), and skin (Stevens et al. *Transplant. Proc.* 1990, 22, 1924), lung allograft rejection (Grossman et al. *Immunol. Allergy Clin. N. Am.* 1989, 9, 153) including chronic lung allograft rejection (obliterative bronchitis; LoCicero et al. *J. Thorac. Cardiovasc. Surg.* 1990, 99, 1059), as well as complications due to total hip replacement (Cirino et al. *Life Sci.* 1996, 59, 86). TNF α has also been linked to infectious diseases (review: Beutler et al. *Crit. Care Med.* 1993, 21, 5423; Degre. *Biotherapy* 1996, 8, 219) including tuberculosis (Rook et al. *Med. Malad. Infect.* 1996, 26, 904), *Helicobacter pylori* infection during peptic ulcer disease (Beales et al. *Gastroenterology* 1997, 112, 136), Chaga's disease resulting from *Trypanosoma cruzi* infection (Chandrasekar et al. *Biochem. Biophys. Res. Commun.* 1996, 223, 365), effects of Shiga-like toxin resulting from *E. coli* infection (Harel et al. *J. Clin. Invest.* 1992, 56, 40), the effects of enterotoxin A resulting from *Staphylococcus* infection (Fischer et al. *J. Immunol.* 1990, 144, 4663), meningococcal infection (Waage et al. *Lancet* 1987, 355; Ossege et al. *J. Neurolog. Sci.* 1996, 144, 1), and infections from *Borrelia burgdorferi* (Brandt et al. *Infect. Immunol.* 1990, 58, 983), *Treponema pallidum* (Chamberlin et al. *Infect. Immunol.* 1989, 57, 2872), cytomegalovirus (CMV; Geist et al. *Am. J. Respir. Cell Mol. Biol.* 1997, 16, 31), influenza virus (Beutler et al. *Clin. Res.* 1986, 34, 491a), Sendai virus (Goldfield et al. *Proc. Nat'l. Acad. Sci. USA* 1989, 87, 1490), Theiler's encephalomyelitis virus (Sierra et al. *Immunology* 1993, 78, 399), and the human immunodeficiency virus (HIV; Poli. *Proc. Nat'l. Acad. Sci. USA* 1990, 87, 782; Vyakarnam et al. *AIDS* 1990, 4, 21; Badley et al. *J. Exp. Med.* 1997, 185, 55).

25 Because inhibition of p38 leads to inhibition of TNF α production, p38 inhibitors will be useful in treatment of the above listed diseases.

A number of diseases are thought to be mediated by excess or undesired matrix-destroying metalloprotease (MMP) activity or by an imbalance in the ratio of the MMPs to the tissue inhibitors of metalloproteinases (TIMPs). These include osteoarthritis (Woessner et al. *J. Biol. Chem.* 1984, 259, 3633), rheumatoid arthritis (Mullins et al.

Biochim. Biophys. Acta 1983, 695, 117; Woolley et al. *Arthritis Rheum.* 1977, 20, 1231; Gravallesse et al. *Arthritis Rheum.* 1991, 34, 1076), septic arthritis (Williams et al. *Arthritis Rheum.* 1990, 33, 533), tumor metastasis (Reich et al. *Cancer Res.* 1988, 48, 3307; Matrisian et al. *Proc. Nat'l. Acad. Sci., USA* 1986, 83, 9413), periodontal diseases
5 (Overall et al. *J. Periodontal Res.* 1987, 22, 81), corneal ulceration (Burns et al. *Invest. Ophthalmol. Vis. Sci.* 1989, 30, 1569), proteinuria (Baricos et al. *Biochem. J.* 1988, 254, 609), coronary thrombosis from atherosclerotic plaque rupture (Henney et al. *Proc. Nat'l. Acad. Sci., USA* 1991, 88, 8154), aneurysmal aortic disease (Vine et al. *Clin. Sci.* 1991, 81, 233), birth control (Woessner et al. *Steroids* 1989, 54, 491), dystrophobic
10 epidermolysis bullosa (Kronberger et al. *J. Invest. Dermatol.* 1982, 79, 208), degenerative cartilage loss following traumatic joint injury, osteopenias mediated by MMP activity, temporomandibular joint disease, and demyelinating diseases of the nervous system (Chantry et al. *J. Neurochem.* 1988, 50, 688).

- 15 Because inhibition of p38 leads to inhibition of MMP production, p38 inhibitors will be useful in treatment of the above listed diseases.

Inhibitors of p38 are active in animal models of TNF α production, including a murine lipopolysaccharide (LPS) model of TNF α production. Inhibitors of p38 are active in a
20 number of standard animal models of inflammatory diseases, including carrageenan-induced edema in the rat paw, arachidonic acid-induced edema in the rat paw, arachidonic acid-induced peritonitis in the mouse, fetal rat long bone resorption, murine type II collagen-induced arthritis, and Freund's adjuvant-induced arthritis in the rat. Thus, inhibitors of p38 will be useful in treating diseases mediated by one or more of the
25 above-mentioned cytokines and/or proteolytic enzymes.

The need for new therapies is especially important in the case of arthritic diseases. The primary disabling effect of osteoarthritis, rheumatoid arthritis and septic arthritis is the progressive loss of articular cartilage and thereby normal joint function. No marketed
30 pharmaceutical agent is able to prevent or slow this cartilage loss, although nonsteroidal antiinflammatory drugs (NSAIDs) have been given to control pain and swelling. The end result of these diseases is total loss of joint function which is only treatable by joint

replacement surgery. P38 inhibitors will halt or reverse the progression of cartilage loss and obviate or delay surgical intervention.

Several patents have appeared claiming polyarylimidazoles and/or compounds containing polyarylimidazoles as inhibitors of p38 (for example, Lee et al. WO 95/07922; Adams et al. WO 95/02591; Adams et al. WO 95/13067; Adams et al. WO 95/31451). It has been reported that arylimidazoles complex to the ferric form of cytochrome P450_{cam} (Harris et al. *Mol. Eng.* 1995, 5, 143, and references therein), causing concern that these compounds may display structure-related toxicity (Howard-Martin et al. *Toxicol. Pathol.* 1987, 15, 369). Therefore, there remains a need for improved p38 inhibitors.


Summary of the Invention

This invention provides compounds, generally described as aryl ureas, including both aryl and heteroaryl analogues, which inhibit p38 mediated events and thus inhibit the production of cytokines (such as TNF α , IL-1 and IL-8) and proteolytic enzymes (such as MMP-1 and MMP-3). The invention also provides a method of treating a cytokine mediated disease state in humans or mammals, wherein the cytokine is one whose production is affected by p38. Examples of such cytokines include, but are not limited to TNF α , IL-1 and IL-8. The invention also provides a method of treating a protease mediated disease state in humans or mammals, wherein the protease is one whose production is affected by p38. Examples of such proteases include, but are not limited to collagenase (MMP-1) and stromelysin (MMP-3).

Accordingly, these compounds are useful therapeutic agents for such acute and chronic inflammatory and/or immunomodulatory diseases as rheumatoid arthritis, osteoarthritis, septic arthritis, rheumatic fever, bone resorption, postmenopausal osteoporosis, sepsis, gram negative sepsis, septic shock, endotoxic shock, toxic shock syndrome, systemic inflammatory response syndrome, inflammatory bowel diseases including Crohn's disease and ulcerative colitis, Jarisch-Herxheimer reactions, asthma, adult respiratory distress syndrome, acute pulmonary fibrotic diseases, pulmonary sarcoidosis, allergic respiratory diseases, silicosis, coal worker's pneumoconiosis, alveolar injury, hepatic failure, liver disease during acute inflammation, severe alcoholic hepatitis, malaria including *Plasmodium falciparum* malaria and cerebral malaria, non-insulin-dependent diabetes mellitus (NIDDM), congestive heart failure, damage following heart disease,

atherosclerosis, Alzheimer's disease, acute encephalitis, brain injury, multiple sclerosis including demyelation and oligiodendrocyte loss in multiple sclerosis, advanced cancer, lymphoid malignancies, tumor metastasis, pancreatitis, including systemic complications in acute pancreatitis, impaired wound healing in infection, inflammation and cancer, 5 periodontal diseases, corneal ulceration, proteinuria, myelodysplastic syndromes, systemic lupus erythematosus, biliary cirrhosis, bowel necrosis, psoriasis, radiation injury, toxicity following administration of monoclonal antibodies such as OKT3, host-versus-graft reactions including ischemia reperfusion injury and allograft rejections including kidney, liver, heart, and skin allograft rejections, lung allograft rejection 10 including chronic lung allograft rejection (obliterative bronchitis) as well as complications due to total hip replacement, and infectious diseases including tuberculosis, Helicobacter pylori infection during peptic ulcer disease, Chaga's disease resulting from Trypanosoma cruzi infection, effects of Shiga-like toxin resulting from E. coli infection, effects of enterotoxin A resulting from Staphylococcus infection, 15 meningococcal infection, and infections from Borrelia burgdorferi, Treponema pallidum, cytomegalovirus, influenza virus, Theiler's encephalomyelitis virus, and the human immunodeficiency virus (HIV).


The present invention, therefore, provides compounds generally described as aryl ureas, 20 including both aryl and heteroaryl analogues, which inhibit the p38 pathway. The invention also provides a method for treatment of p38-mediated disease states in humans or mammals, e.g., disease states mediated by one or more cytokines or proteolytic enzymes produced and/or activated by a p38 mediated process. Thus, the invention is directed to compounds and methods for the treatment of diseases mediated by p38 kinase 25 comprising administering a compound of Formula I



I

30 wherein

A is



B is a substituted or unsubstituted, up to tricyclic aryl or heteroaryl moiety of up to 30 carbon atoms with at least one 6-member aromatic structure containing 0-4 members of the group consisting of nitrogen, oxygen and sulfur, wherein if B is substituted, it is substituted by one or more substituents selected from the group consisting of halogen, up to per-halo, and W_n, wherein n is 0-3 and each W is independently selected from the group consisting of -CN, -CO₂R⁷, -C(O)NR⁷R⁷, -C(O)-R⁷, -NO₂, -OR⁷, -SR⁷, -NR⁷R⁷, -NR⁷C(O)OR⁷, -NR⁷C(O)R⁷, C₁-C₁₀ alkyl, C₂₋₁₀-alkenyl, C₁₋₁₀-alkoxy, C₃-C₁₀ cycloalkyl, C₆-C₁₄ aryl, C₇-C₂₄ alkaryl, C₃-C₁₃ heteroaryl, C₄-C₂₃ alkheteroaryl, substituted C₁-C₁₀ alkyl, substituted C₂₋₁₀-alkenyl, substituted C₁₋₁₀-alkoxy, substituted C₃-C₁₀ cycloalkyl, substituted C₄-C₂₃ alkheteroaryl and Q-Ar;

wherein if W is a substituted group, it is substituted by one or more substituents independently selected from the group consisting of -CN, -CO₂R⁷, -C(O)R⁷, -C(O)NR⁷R⁷, -OR⁷, -SR⁷, -NR⁷R⁷, NO₂, -NR⁷C(O)R⁷, -NR⁷C(O)OR⁷ and halogen up to per-halo;


wherein each R⁷ is independently selected from H, C₁-C₁₀ alkyl, C₂₋₁₀-alkenyl, C₃-C₁₀ cycloalkyl, C₆-C₁₄ aryl, C₃-C₁₃ hetaryl, C₇-C₂₄ alkaryl, C₄-C₂₃ alkheteroaryl, up to per-halosubstituted C₁-C₁₀ alkyl, up to per-halosubstituted C₂₋₁₀-alkenyl, up to per-halosubstituted C₃-C₁₀ cycloalkyl, up to per-halosubstituted C₆-C₁₄ aryl and up to per-halosubstituted C₃-C₁₃ hetaryl,

wherein Q is -O-, -S-, -N(R⁷)-, -(CH₂)_m-, -C(O)-, -CH(OH)-, -(CH₂)_mO-, -NR⁷C(O)NR⁷R⁷-, -NR⁷C(O)-, -C(O)NR⁷-, -(CH₂)_mS-, -(CH₂)_mN(R⁷)-, -O(CH₂)_m-, -CHX^a, -CX^a₂-, -S-(CH₂)_m- and -N(R⁷)(CH₂)_m-,

m = 1-3, and X^a is halogen; and


Ar is a 5-10 member aromatic structure containing 0-2 members of the group consisting of nitrogen, oxygen and sulfur, which is unsubstituted or substituted by halogen up to per-halo and optionally substituted by Z_{n1} , wherein $n1$ is 0 to 3 and each Z is independently selected from the group consisting of of $-CN$, $-CO_2R^7$, $-C(O)NR^7R^7$,
 5 $-C(O)-NR^7$, $-C(O)R^7$, $-NO_2$, $-OR^7$, $-SR^7$, $-NR^7R^7$, $-NR^7C(O)OR^7$, $-NR^7C(O)R^7$, C_1-C_{10} alkyl, C_3-C_{10} cycloalkyl, C_6-C_{14} aryl, C_3-C_{13} hetaryl, C_7-C_{24} alkaryl, C_4-C_{23} alkheteroaryl, substituted C_1-C_{10} alkyl, substituted C_3-C_{10} cycloalkyl, substituted C_7-C_{24} alkaryl and substituted C_4-C_{23} alkheteroaryl; wherein the one or more substituents of Z is selected from the group consisting of $-CN$, $-CO_2R^7$, $-C(O)NR^7R^7$, $-OR^7$, $-SR^7$, $-NO_2$,
 10 $-NR^7R^7$, $-NR^7C(O)R^7$, $-NR^7C(O)OR^7$,

R^3 , R^4 , R^5 are each independently H, C_{1-10} -alkyl, optionally substituted by halogen, up to perhalo, C_{1-10} alkoxy, optionally substituted by halogen, up to perhaloalkoxy, halogen; NO_2 or NH_2 ;
 15 R^6 is H, C_{1-10} -alkyl, C_{1-10} alkoxy, $-NHCOR^1$; $-NR^1COR^1$; NO_2 ;




one of R^4 , R^5 or R^6 can be $-X-Y$,
 or 2 adjacent R^4-R^6 can together be an aryl or hetaryl ring with 5-12 atoms, optionally substituted by C_{1-10} -alkyl, C_{1-10} alkoxy, C_{3-10} cycloalkyl, C_{2-10} alkenyl,
 20 C_{1-10} alkanoyl, C_{6-12} aryl, C_{5-12} hetaryl or C_{6-12} aralkyl;
 R^1 is C_{1-10} -alkyl optionally substituted by halogen, up to perhalo;
 X is $-CH_2-$, $-S-$, $-N(CH_3)-$, $-NHC(O)-$, $-CH_2-S-$, $-S-CH_2-$, $-C(O)-$, or $-O-$; and
 X is additionally a single bond where Y is pyridyl;
 Y is phenyl, pyridyl, naphthyl, pyridone, pyrazine, benzodioxane, benzopyridine,
 25 pyrimidine or benzothiazole, each optionally substituted by

C₁₋₁₀-alkyl, C₁₋₁₀-alkoxy, halogen, OH, -SCH₃ or NO₂ or, where Y is phenyl, by



or a pharmaceutically acceptable salt thereof.

Preferably, the compounds of formula I are of formula Ia




5

wherein

R³, R⁴, R⁵ and R⁶ are each independently H, halogen, C₁₋₁₀-alkyl optionally substituted by halogen, up to perhalo, C₁₋₁₀-alkoxy, optionally substituted by at least one hydroxy group or by halogen, up to perhalo; C₆₋₁₂ aryl, optionally substituted by C₁₋₁₀ alkoxy or halogen, C₅₋₁₂ hetaryl, optionally substituted by C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy or halogen; NO₂, SO₂F or -SO₂CH₂X_{3-p}; -COOR¹; -OR¹CONHR¹; -NHCOR¹; -SR¹; phenyl optionally substituted by halo or C₁₋₁₀-alkoxy; NH₂; -N(SO₂R¹)₂, furyloxy,

10



2 adjacent R³-R⁶ can together form an aryl or hetaryl ring with 5-12 atoms, optionally substituted by C₁₋₁₀-alkyl, C₁₋₁₀-alkoxy, C₃₋₁₀-cycloalkyl, C₂₋₁₀-alkenyl, C₁₋₁₀-alkanoyl, C₆₋₁₂-aryl, C₅₋₁₂-hetaryl, C₆₋₁₂-aralkyl, C₆₋₁₂-alkaryl, halogen; -NR¹; -NO₂; -CF₃;

15

-COOR¹; -NHCOR¹; -CN; -CONR¹R¹; -SO₂R²; -SOR²; -SR²; in which R¹ is H or C₁₋₁₀-alkyl and R² is C₁₋₁₀-alkyl; optionally substituted by halogen, up to perhalo, with -SO₂- optionally incorporated in the aryl or hetaryl ring;


5 one of R⁴, R⁵ or R⁶ can be -X-Y,

R¹ is C₁₋₁₀-alkyl, optionally substituted by halogen, up to perhalo;

p is 0 or 1;

X is -CH₂-, -S-, N(CH₃)-, -NHC(O)-, CH₂-S-, -S-CH₂-, -C(O)-, or -O-; and

Y is phenyl, pyridyl, naphthyl, pyridone, pyrazine, benzodioxane, benzopyridine,
10 pyrimidine or benzothiazole, each optionally substituted by C₁₋₁₀-alkyl,
C₁₋₁₀-alkoxy, halogen or NO₂ or, where Y is phenyl, by



15 with the proviso that if R³ and R⁶ are both H, one of R⁴ or R⁵ is not H.

In formula I, suitable hetaryl groups B include, but are not limited to, 5-12 carbon-atom
20 aromatic rings or ring systems containing 1-3 rings, at least one of which is aromatic, in
which one or more, e.g., 1-4 carbon atoms in one or more of the rings can be replaced by
oxygen, nitrogen or sulfur atoms. Each ring typically has 3-7 atoms. For example, B can
be 2- or 3-furyl, 2- or 3-thienyl, 2- or 4-triazinyl, 1-, 2- or 3-pyrrolyl, 1-, 2-, 4- or 5-
imidazolyl, 1-, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or
25 5-thiazolyl, 3-, 4- or 5-isothiazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, 1,2,3-
triazol-1-, -4- or -5-yl, 1,2,4-triazol-1-, -3- or -5-yl, 1- or 5-tetrazolyl, 1,2,3-oxadiazol-4-
or -5-yl, 1,2,4-oxadiazol-3- or -5-yl, 1,3,4-thiadiazol-2- or -5-yl, 1,2,4-oxadiazol-3- or -
5-yl, 1,3,4-thiadiazol-2- or -5-yl, 1,3,4-thiadiazol-3- or -5-yl, 1,2,3-thiadiazol-4- or -5-yl,
2-, 3-, 4-, 5- or 6-2H-thiopyranyl, 2-, 3- or 4-4H-thiopyranyl, 3- or 4-pyridazinyl,
30 pyrazinyl, 2-, 3-, 4-, 5-, 6- or 7-benzofuryl, 2-, 3-, 4-, 5-, 6- or 7-benzothieryl, 1-, 2-, 3-,
4-, 5-, 6- or 7-indolyl, 1-, 2-, 4- or 5-benzimidazolyl, 1-, 3-, 4-, 5-, 6- or 7-
benzopyrazolyl, 2-, 4-, 5-, 6- or 7-benzoxazolyl, 3-, 4-, 5- 6- or 7-benzisoxazolyl, 1-, 3-,

4-, 5-, 6- or 7-benzothiazolyl, 2-, 4-, 5-, 6- or 7-benzisothiazolyl, 2-, 4-, 5-, 6- or 7-benz-
 1,3-oxadiazolyl, 2-, 3-, 4-, 5-, 6-, 7- or 8-quinoliny, 1-, 3-, 4-, 5-, 6-, 7-, 8- isoquinoliny,
 1-, 2-, 3-, 4- or 9-carbazolyl, 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8- or 9-acridiny, or 2-, 4-, 5-, 6-, 7-
 or 8-quinazoliny, or additionally optionally substituted phenyl, 2- or 3-thienyl, 1,3,4-
 5 thiadiazolyl, 3-pyrryl, 3-pyrazolyl, 2-thiazolyl or 5-thiazolyl, etc. For example, B can be
 4-methyl-phenyl, 5-methyl-2-thienyl, 4-methyl-2-thienyl, 1-methyl-3-pyrryl, 1-methyl-3-
 pyrazolyl, 5-methyl-2-thiazolyl or 5-methyl-1,2,4-thiadiazol-2-yl.

Suitable alkyl groups and alkyl portions of groups, e.g., alkoxy, etc. throughout include
 10 methyl, ethyl, propyl, butyl, etc., including all straight-chain and branched isomers such
 as isopropyl, isobutyl, *sec*-butyl, *tert*-butyl, etc.

Suitable aryl groups include, for example, phenyl and 1- and 2-naphthyl.

15 The term "cycloalkyl", as used herein, refers to cyclic structures with or without alkyl
 substituents such that, for example, "C₄ cycloalkyl" includes methyl substituted
 cyclopropyl groups as well as cyclobutyl groups. The term "cycloalkyl" also includes
 saturated heterocyclic groups.


20 Suitable halogen groups include F, Cl, Br, and/or I, from one to per-substitution (i.e. all H
 atoms on a group replaced by a halogen atom) being possible where an alkyl group is
 substituted by halogen, mixed substitution of halogen atom types also being possible on a
 given moiety.

25 Preferred compounds of formula I include those where R³ is H, halogen or C₁₋₁₀-alkyl,
 optionally substituted by halogen, up to perhalo, NO₂, -SO₂F, -SO₂CHF₂; or -SO₂CF₃; R⁴
 is H, C₁₋₁₀-alkyl, C₁₋₁₀-alkoxy, halogen or NO₂; R⁵ is H, C₁₋₁₀-alkyl optionally substituted
 by halogen, up to perhalo; R⁶ is H, hydroxy, C₁₋₁₀-alkoxy, optionally substituted by at
 least one hydroxy group; -COOR¹; -OR¹CONHR¹; -NHCOR¹; -SR¹; phenyl optionally
 30 substituted by halo or C₁₋₁₀-alkoxy; NH₂; -N(SO₂R¹)₂, furyloxy,


Preferably, R³ is Cl, F, C₄₋₅-branched alkyl, -SO₂F or -SO₂CF₃; and R⁶ is hydroxy;
 C₁₋₁₀-alkoxy optionally substituted by at least one hydroxy group; -COOR¹; -

OR¹CONHR¹; -NHCOR¹; -SR¹; phenyl optionally substituted by halo or C₁₋₁₀-alkoxy; NH₂; -N(SO₂R¹)₂, furyloxy,

More preferably, R⁶ is t-butyl or CF₃, and R⁶ is -OCH₃. Preferably, R⁴ is C₁₋₁₀-alkyl or halogen; R⁵ is H, C₁₋₁₀-alkyl, halogen, CF₃, halogen, NO₂ or NH₂; and R⁶ is H, C₁₋₁₀-alkyl, halogen, -NHCOCH₃, -N(CH₃)COCH₃, NO₂,




The invention also relates to compounds *per se*, of formula II



10

wherein


R³, R⁴, R⁵ and R⁶ are each independently H, halogen, C₁₋₁₀-alkyl optionally substituted by halogen up to perhalo, C₁₋₁₀-alkoxy, optionally substituted by at least one hydroxy group or halogen, up to perhalo; NO₂, SO₂F or -SO₂CH₂X₃₋₈, C₁₋₁₀-alkoxy; -COOR¹;
 15 -OR¹CONHR¹; -NHCOR¹; -SR¹; C₆₋₁₂ aryl, optionally substituted by C₁₋₁₀-alkyl, C₁₋₁₀ alkoxy or halogen, C₅₋₁₂ hetaryl, optionally substituted by C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy or halogen; NH₂; -N(SO₂R¹)₂; furyloxy;



- 2 adjacent R^3 - R^6 can together form an aryl or hetaryl ring with 5-12 atoms, optionally substituted by C_{1-10} -alkyl, C_{1-10} -alkoxy, C_{3-10} -cycloalkyl, C_{2-10} -alkenyl, C_{1-10} -alkanoyl, C_{6-12} -aryl, C_{5-12} -hetaryl, C_{6-12} -aralkyl, C_{6-12} -alkaryl, halogen; $-NR^1$; $-NO_2$; $-CF_3$; $-COOR^1$; $-NHCOR^1$; $-CN$; $-CONR^1R^1$; $-SO_2R^2$; $-SOR^2$; $-SR^2$; in which R^1 is H or C_{1-10} -alkyl and R^2 is C_{1-10} -alkyl;
- 5

R^3 , R^4 and R^5 are each independently H, C_{1-10} -alkyl, optionally substituted by halogen, up to perhalo; NO_2 or NH_2 ;

R^6 is H, C_{1-10} -alkyl, halogen, $-NHCOR^1$; $-NR^1COR^1$; NO_2 ;



10

2 adjacent R^4 - R^6 can together be an aryl or hetaryl ring with 5-12 atoms;


R^1 is C_{1-10} -alkyl, optionally substituted by halogen, up to perhalo;

n is 0 or 1;

- 15 with the provisos that

(a) if R^3 and R^6 are both H, one of R^4 or R^5 is not H, and


(b) that R^6 is phenyl substituted by alkoxy or halogen, alkoxy substituted by hydroxy, $-SO_2CF_2H$, $-OR^1CONHR^1$,



20

furyloxy or $-N(SO_2R^1)_2$;

or R^6 is



and (c) if R⁶ is phenyl substituted by alkoxy or halogen, the compounds have a pK_a greater than 10, e.g., greater than 12, preferably greater than 15.

Preferred 5-tert-butylphenyl ureas are:

- 5 N-(5-tert-Butyl-2-methoxyphenyl)-N'-(4-phenyloxyphenyl)urea;
 N-(5-tert-Butyl-2-methoxyphenyl)-N'-(4-(4-methoxyphenyloxy)phenyl)urea;
 N-(5-tert-Butyl-2-methoxyphenyl)-N'-(4-(4-pyridinyloxy)phenyl)urea;
 N-(5-tert-Butyl-2-methoxyphenyl)-N'-(4-(4-pyridinylmethyl)phenyl)urea;
 N-(5-tert-Butyl-2-methoxyphenyl)-N'-(4-(4-pyridinylthio)phenyl)urea;
 10 N-(5-tert-Butyl-2-methoxyphenyl)-N'-(4-(4-(4,7-methano-1H-isoindole-1,3(2H)-
 dionyl)methyl)phenyl)urea;
 N-(5-tert-Butyl-2-phenylphenyl)-N'-(2,3-dichlorophenyl)urea;
 N-(5-tert-Butyl-2-(3-thienyl)phenyl)-N'-(2,3-dichlorophenyl)urea;
 N-(5-tert-Butyl-2-(N-methylaminocarbonyl)methoxyphenyl)-N'-(2,3-
 15 dichlorophenyl)urea;
 N-(5-tert-Butyl-2-(N-methylaminocarbonyl)methoxyphenyl)-N'-(1-naphthyl)urea;
 N-(5-tert-Butyl-2-(N-morpholinocarbonyl)methoxyphenyl)-N'-(2,3-
 dichlorophenyl)urea;
 N-(5-tert-Butyl-2-(N-morpholinocarbonyl)methoxyphenyl)-N'-(1-naphthyl)urea;
 20 N-(5-tert-Butyl-2-(3-tetrahydrofuranlyoxy)phenyl)-N'-(2,3-dichlorophenyl)urea;
 and
 N-(5-tert-Butyl-2-methoxyphenyl)-N'-(4-(3-pyridinyl)methylphenyl)urea.

Preferred 5-trifluoromethylphenyl ureas are:

- 25 N-(5-Trifluoromethyl-2-methoxyphenyl)-N'-(4-methylphenyl)urea;
 N-(5-Trifluoromethyl-2-methoxyphenyl)-N'-(4-methyl-2-fluorophenyl)urea;
 N-(5-Trifluoromethyl-2-methoxyphenyl)-N'-(4-fluoro-3-chlorophenyl)urea;
 N-(5-Trifluoromethyl-2-methoxyphenyl)-N'-(4-methyl-3-chlorophenyl)urea;
 N-(5-Trifluoromethyl-2-methoxyphenyl)-N'-(4-methyl-3-fluorophenyl)urea;
 30 N-(5-Trifluoromethyl-2-methoxyphenyl)-N'-(2,4-difluorophenyl)urea;
 N-(5-Trifluoromethyl-2-methoxyphenyl)-N'-(4-phenyloxy-3,5-

dichlorophenyl)urea;

N-(5-Trifluoromethyl-2-methoxyphenyl)-N'-(4-(4-pyridinylmethyl)phenyl)urea;

N-(5-Trifluoromethyl-2-methoxyphenyl)-N'-(4-(4-pyridinylthio)phenyl)urea;

N-(5-Trifluoromethyl-2-methoxyphenyl)-N'-(4-(4-pyridinyloxy)phenyl)urea;

5 N-(5-Trifluoromethyl-2-methoxyphenyl)-N'-(3-(4-pyridinylthio)phenyl)urea; and

N-(5-Trifluoromethyl-2-methoxyphenyl)-N'-(4-(3-(N-methylaminocarbonyl)-phenyloxy)phenyl)-urea.

Preferred 5-sulfonylphenyl ureas are:

10 N-(5-Fluorosulfonyl)-2-methoxyphenyl)-N'-(4-methylphenyl)urea;

N-(5-(Difluoromethanesulfonyl)-2-methoxyphenyl)-N'-(4-methylphenyl)urea
N-(5-(Difluoromethanesulfonyl)-2-methoxyphenyl)-N'-(4-fluorophenyl)urea;

N-(5-(Difluoromethanesulfonyl)-2-methoxyphenyl)-N'-(4-methyl-2-fluorophenyl)urea;

15 N-(5-(Difluoromethanesulfonyl)-2-methoxyphenyl)-N'-(4-methyl-3-fluorophenyl)urea;

N-(5-(Difluoromethanesulfonyl)-2-methoxyphenyl)-N'-(4-methyl-3-chlorophenyl)urea;

N-(5-(Difluoromethanesulfonyl)-2-methoxyphenyl)-N'-(4-fluoro-3-chlorophenyl)urea;

20 N-(5-(Difluoromethanesulfonyl)-2-methoxyphenyl)-N'-(4-fluoro-3-methylphenyl)urea;

N-(5-(Difluoromethanesulfonyl)-2-methoxyphenyl)-N'-(2,3-dimethylphenyl)urea;

and

25 N-(5-(Trifluoromethanesulfonyl)-2-methoxyphenyl)-N'-(4-methylphenyl)urea.

Preferred 2-naphthyl ureas are:

N-(3-Methoxy-2-naphthyl)-N'-(2-fluorophenyl)urea;

N-(3-Methoxy-2-naphthyl)-N'-(4-methylphenyl)urea;

30 N-(3-Methoxy-2-naphthyl)-N'-(3-fluorophenyl)urea;

N-(3-Methoxy-2-naphthyl)-N'-(4-methyl-3-fluorophenyl)urea;

- N-(3-Methoxy-2-naphthyl)-N'-(2,3-dimethylphenyl)urea;
 N-(3-Methoxy-2-naphthyl)-N'-(1-naphthyl)urea;
 N-(3-Methoxy-2-naphthyl)-N'-(4-(4-pyridinylmethyl)phenyl)urea;
 N-(3-Methoxy-2-naphthyl)-N'-(4-(4-pyridinylthio)phenyl)urea;
 5 N-(3-Methoxy-2-naphthyl)-N'-(4-(4-methoxyphenoxy)phenyl)urea; and
 N-(3-Methoxy-2-naphthyl)-N'-(4-(4-(4,7-methano-1H-isoindole-1,3(2H)-
 dionyl)methyl)phenyl)urea.

Other preferred ureas are:

- 10 N-(2-Hydroxy-4-nitro-5-chlorophenyl)-N'-(phenyl)urea; and
 N-(2-Hydroxy-4-nitro-5-chlorophenyl)-N'-(4-(4-pyridinylmethyl)phenyl)urea.

The present invention is also directed to pharmaceutically acceptable salts of formula I. Suitable pharmaceutically acceptable salts are well known to those skilled in the art and
 15 include basic salts of inorganic and organic acids, such as hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, sulphonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, and mandelic acid. In addition, pharmaceutically acceptable salts include acid salts of
 20 inorganic bases, such as salts containing alkaline cations (e.g., Li^+ , Na^+ or K^+), alkaline earth cations (e.g., Mg^{+2} , Ca^{+2} or Ba^{+2}), the ammonium cation, as well as acid salts of organic bases, including aliphatic and aromatic substituted ammonium, and quaternary ammonium cations, such as those arising from protonation or peralkylation of triethylamine, *N,N*-diethylamine, *N,N*-dicyclohexylamine, pyridine, *N,N*-
 25 dimethylaminopyridine (DMAP), 1,4-diazabicyclo[2.2.2]octane (DABCO), 1,5-diazabicyclo[4.3.0]non-5-ene (DBN) and 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU).


A number of the compounds of Formula I possess asymmetric carbons and can therefore exist in racemic and optically active forms. Methods of separation of enantiomeric and
 30 diastereomeric mixtures are well known to one skilled in the art. The present invention

encompasses any isolated racemic or optically active form of compounds described in Formula I which possess p38 kinase inhibitory activity.

General Preparative Methods

- 5 The compounds of Formula I may be prepared by use of known chemical reactions and procedures, some from starting materials which are commercially available. Nevertheless, the following general preparative methods are presented to aid one of skill in the art in synthesizing these compounds, with more detailed particular examples being presented in the experimental section describing the working examples.


10



Scheme I Reduction of Nitroaryls to Aryl Amines


Nitroaryls are commonly formed by electrophilic aromatic nitration using HNO_3 , or an alternative NO_2^+ source. Nitroaryls may be further elaborated prior to reduction. Thus,

- 15 nitroaryls substituted with




potential leaving groups (eg. F, Cl, Br, etc.) may undergo substitution reactions on treatment with nucleophiles, such as thiolate (exemplified in Scheme II) or phenoxide. Nitroaryls may also undergo Ullman-type coupling reactions (Scheme II).

19



Scheme II Selected Nucleophilic Aromatic Substitution using Nitroaryls

Nitroaryls may also undergo transition metal mediated cross coupling reactions. For example, nitroaryl electrophiles, such as nitroaryl bromides, iodides or triflates, undergo palladium mediated cross coupling reactions with aryl nucleophiles, such as arylboronic acids (Suzuki reactions, exemplified below), aryltins (Stille reactions) or arylzincs (Negishi reaction) to afford the biaryl (5).




10

Either nitroaryls or anilines may be converted into the corresponding arenesulfonyl chloride (7) on treatment with chlorosulfonic acid. Reaction of the sulfonyl chloride with a fluoride source, such as KF then affords sulfonyl fluoride (8). Reaction of sulfonyl fluoride 8 with trimethylsilyl trifluoromethane in the presence of a fluoride source, such as tris(dimethylamino)sulfonium difluorotrimethylsiliconate (TASF) leads to the corresponding trifluoromethylsulfone (9). Alternatively, sulfonyl chloride 7 may be reduced to the arenethiol (10), for example with zinc amalgam. Reaction of thiol 10 with CHClF_2 in the presence of base gives the difluoromethyl mercaptam (11), which may be oxidized to the sulfone (12) with any of a variety of oxidants, including CrO_3 -acetic anhydride (Sedova et al. *Zh. Org. Khim.* 1970, 6, 568).


20

20



Scheme III Selected Methods of Fluorinated Aryl Sulfone Synthesis

As shown in Scheme IV, non-symmetrical urea formation may involve reaction of an aryl isocyanate (14) with an aryl amine (13). The heteroaryl isocyanate may be synthesized from a heteroaryl amine by treatment with phosgene or a phosgene equivalent, such as trichloromethyl chloroformate (diphosgene), bis(trichloromethyl) carbonate (triphosgene), or *N,N'*-carbonyldiimidazole (CDI). The isocyanate may also be derived from a heterocyclic carboxylic acid derivative, such as an ester, an acid halide or an anhydride by a Curtius-type rearrangement. Thus, reaction of acid derivative 16 with an azide source, followed by rearrangement affords the isocyanate. The corresponding carboxylic acid (17) may also be subjected to Curtius-type rearrangements using diphenylphosphoryl azide (DPPA) or a similar reagent.



Scheme IV Selected Methods of Non-Symmetrical Urea Formation

Finally, ureas may be further manipulated using methods familiar to those skilled in the art.

The invention also includes pharmaceutical compositions including a compound of Formula I, and a physiologically acceptable carrier.

The compounds may be administered orally, topically, parenterally, by inhalation or spray, vaginally, rectally or sublingually in dosage unit formulations. The term 'administration by injection' includes intravenous, intramuscular, subcutaneous and parenteral injections, as well as use of infusion techniques. Dermal administration may include topical application or transdermal administration. One or more compounds may be present in association with one or more non-toxic pharmaceutically acceptable carriers and if desired other active ingredients.

Compositions intended for oral use may be prepared according to any suitable method known to the art for the manufacture of pharmaceutical compositions. Such compositions may contain one or more agents selected from the group consisting of diluents, sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture

of tablets. These excipients may be, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; and binding agents, for example magnesium stearate, stearic acid or talc. The tablets may be
5 uncoated or they may be coated by known techniques to delay disintegration and adsorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. These compounds may also be prepared in solid, rapidly released form.

10

Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin or olive oil.

15

Aqueous suspensions containing the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions may also be used. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxypropyl-methylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth
20 and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example, lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol such as
25 polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl, *p*-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose
30 or saccharin.

Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or
35 wetting agents and suspending agents are exemplified by those already mentioned above.

Additional excipients, for example, sweetening, flavoring and coloring agents, may also be present.

5 The compounds may also be in the form of non-aqueous liquid formulations, e.g., oily suspensions which may be formulated by suspending the active ingredients in a vegetable oil, for example arachis oil, olive oil, sesame oil or peanut oil, or in a mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide palatable oral preparations. These
10 compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.

Compounds of the invention may also be administrated transdermally using methods known to those skilled in the art (see, for example: Chien; "Transdermal Controlled Systemic Medications"; Marcel Dekker, Inc.; 1987. Lipp et al. WO94/04157 3Mar94).
15 For example, a solution or suspension of a compound of Formula I in a suitable volatile solvent optionally containing penetration enhancing agents can be combined with additional additives known to those skilled in the art, such as matrix materials and bacteriocides. After sterilization, the resulting mixture can be formulated following known procedures into dosage forms. In addition, on treatment with emulsifying agents
20 and water, a solution or suspension of a compound of Formula I may be formulated into a lotion or salve.

Suitable solvents for processing transdermal delivery systems are known to those skilled in the art, and include lower alcohols such as ethanol or isopropyl alcohol, lower ketones
25 such as acetone, lower carboxylic acid esters such as ethyl acetate, polar ethers such as tetrahydrofuran, lower hydrocarbons such as hexane, cyclohexane or benzene, or halogenated hydrocarbons such as dichloromethane, chloroform, trichlorotrifluoroethane, or trichlorofluoroethane. Suitable solvents may also include mixtures of one or more materials selected from lower alcohols, lower ketones, lower carboxylic acid esters, polar
30 ethers, lower hydrocarbons, halogenated hydrocarbons.

Suitable penetration enhancing materials for transdermal delivery system are known to those skilled in the art, and include, for example, monohydroxy or polyhydroxy alcohols

such as ethanol, propylene glycol or benzyl alcohol, saturated or unsaturated C₈-C₁₈ fatty alcohols such as lauryl alcohol or cetyl alcohol, saturated or unsaturated C₈-C₁₈ fatty acids such as stearic acid, saturated or unsaturated fatty esters with up to 24 carbons such as methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl isobutyl tertbutyl or monoglycerin esters of acetic acid, capronic acid, lauric acid, myristinic acid, stearic acid, or palmitic acid, or diesters of saturated or unsaturated dicarboxylic acids with a total of up to 24 carbons such as diisopropyl adipate, diisobutyl adipate, diisopropyl sebacate, diisopropyl maleate, or diisopropyl fumarate. Additional penetration enhancing materials include phosphatidyl derivatives such as lecithin or cephalin, terpenes, amides, ketones, ureas and their derivatives, and ethers such as dimethyl isosorbide and diethyleneglycol monoethyl ether. Suitable penetration enhancing formulations may also include mixtures of one or more materials selected from monohydroxy or polyhydroxy alcohols, saturated or unsaturated C₈-C₁₈ fatty alcohols, saturated or unsaturated C₈-C₁₈ fatty acids, saturated or unsaturated fatty esters with up to 24 carbons, diesters of saturated or unsaturated dicarboxylic acids with a total of up to 24 carbons, phosphatidyl derivatives, terpenes, amides, ketones, ureas and their derivatives, and ethers.

Suitable binding materials for transdermal delivery systems are known to those skilled in the art and include polyacrylates, silicones, polyurethanes, block polymers, styrenebutadiene copolymers, and natural and synthetic rubbers. Cellulose ethers, derivatized polyethylenes, and silicates may also be used as matrix components. Additional additives, such as viscous resins or oils may be added to increase the viscosity of the matrix.

Pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions. The oil phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example

polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening and flavoring agents.

5 Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents.

10 The compounds may also be administered in the form of suppositories for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal or vaginal temperature and will therefore melt in the rectum or vagina to release the drug. Such materials include cocoa butter and polyethylene glycols.

15 For all regimens of use disclosed herein for compounds of Formula I, the daily oral dosage regimen will preferably be from 0.01 to 200 mg/Kg of total body weight. The daily dosage for administration by injection, including intravenous, intramuscular, subcutaneous and parenteral injections, and use of infusion techniques will preferably be from 0.01 to 200 mg/Kg of total body weight. The daily vaginal dosage regimen will preferably be from 0.01 to 200 mg/Kg of total body weight. The daily rectal dosage
20 regimen will preferably be from 0.01 to 200 mg/Kg of total body weight. The transdermal concentration will preferably be that required to maintain a daily dose of from 0.01 to 200 mg/Kg. The daily topical dosage regimen will preferably be from 0.1 to 200 mg administered between one to four times daily. The daily inhalation dosage regimen will preferably be from 0.01 to 10 mg/Kg of total body weight.

25

It will be appreciated by those skilled in the art that the particular method of administration will depend on a variety of factors, all of which are considered routinely when administering therapeutics. It will also be understood, however, that the specific dose level for a given patient depends on a variety of factors, including specific activity
30 of the compound administered, the age of the patient, the body weight of the patient, the general health of the patient, the gender of the patient, the diet of the patient, time of administration, route of administration, rate of excretion, drug combination, and the severity of the condition undergoing therapy, etc. It will be further appreciated by one skilled in the art that the optimal course of treatment, i.e., the mode of treatment and the
35 daily number of doses of a compound of Formula I or a pharmaceutically acceptable salt

thereof given for a defined number of days, can be ascertained by those skilled in the art using conventional course of treatment tests.

5 The compounds of Figure I are producible from known compounds (or from starting materials which, in turn, are producible from known compounds), e.g., through the general preparative methods shown above. The activity of a given compound to inhibit raf kinase can be routinely assayed, e.g., according to procedures disclosed below. The following examples are for illustrative purposes only and are not intended, nor should they be construed to limit the invention in any way.

10

The entire disclosure of all applications, patents and publications cited above and below are hereby incorporated by reference, including provisional application serial number attorney docket number Bayer 10-V1, filed on December 22, 1997 as serial number 08/995,749, and converted on December 22, 1998.

15

The following examples are for illustrative purposes only and are not intended, nor should they be construed to limit the invention in any way.

EXAMPLES

20 All reactions were performed in flame-dried or oven-dried glassware under a positive pressure of dry argon or dry nitrogen, and were stirred magnetically unless otherwise indicated. Sensitive liquids and solutions were transferred via syringe or cannula, and introduced into reaction vessels through rubber septa. Unless otherwise stated, the term 'concentration under reduced pressure' refers to use of a Buchi rotary evaporator at
25 approximately 15 mmHg.

All temperatures are reported uncorrected in degrees Celsius (°C). Unless otherwise indicated, all parts and percentages are by weight.

30 Commercial grade reagents and solvents were used without further purification. Thin-layer chromatography (TLC) was performed using Whatman® pre-coated glass-backed silica gel 60A F-254 250 µm plates. Visualization of plates was effected by one or more of the following techniques: (a) ultraviolet illumination, (b) exposure to iodine vapor, (c)

immersion of the plate in a 10% solution of phosphomolybdic acid in ethanol followed by heating, (d) immersion of the plate in a cerium sulfate solution followed by heating, and/or (e) immersion of the plate in an acidic ethanol solution of 2,4-dinitrophenylhydrazine followed by heating. Column chromatography (flash chromatography) was performed using 230-400 mesh EM Science[®] silica gel.


Melting points (mp) were determined using a Thomas-Hoover melting point apparatus or a Mettler FP66 automated melting point apparatus and are uncorrected. Fourier transform infrared spectra were obtained using a Mattson 4020 Galaxy Series spectrophotometer. Proton (¹H) nuclear magnetic resonance (NMR) spectra were measured with a General Electric GN-Omega 300 (300 MHz) spectrometer with either Me₄Si (δ 0.00) or residual protonated solvent (CHCl₃, δ 7.26; MeOH δ 3.30; DMSO δ 2.49) as standard. Carbon (¹³C) NMR spectra were measured with a General Electric GN-Omega 300 (75 MHz) spectrometer with solvent (CDCl₃, δ 77.0; MeOD-d₃, δ 49.0; DMSO-d₆, δ 39.5) as standard. Low resolution mass spectra (MS) and high resolution mass spectra (HRMS) were either obtained as electron impact (EI) mass spectra or as fast atom bombardment (FAB) mass spectra. Electron impact mass spectra (EI-MS) were obtained with a Hewlett Packard 5989A mass spectrometer equipped with a Vacumetrics Desorption Chemical Ionization Probe for sample introduction. The ion source was maintained at 250 °C. Electron impact ionization was performed with electron energy of 70 eV and a trap current of 300 μA. Liquid-caesium secondary ion mass spectra (FAB-MS), an updated version of fast atom bombardment were obtained using a Kratos Concept 1-H spectrometer. Chemical ionization mass spectra (CI-MS) were obtained using a Hewlett Packard MS-Engine (5989A) with methane or ammonia as the reagent gas (1x10⁻⁴ torr to 2.5x10⁻⁴ torr). The direct insertion desorption chemical ionization (DCI) probe (Vacumetrics, Inc.) was ramped from 0-1.5 amps in 10 sec and held at 10 amps until all traces of the sample disappeared (~1-2 min). Spectra were scanned from 50-800 amu at 2 sec per scan. HPLC - electrospray mass spectra (HPLC ES-MS) were obtained using a Hewlett-Packard 1100 HPLC equipped with a quaternary pump, a variable wavelength detector, a C-18 column, and a Finnigan LCQ ion trap mass spectrometer with electrospray ionization. Spectra were scanned from 120-800 amu

using a variable ion time according to the number of ions in the source. Gas chromatography - ion selective mass spectra (GC-MS) were obtained with a Hewlett Packard 5890 gas chromatograph equipped with an HP-1 methyl silicone column (0.33 mM coating; 25 m x 0.2 mm) and a Hewlett Packard 5971 Mass Selective Detector
5 (ionization energy 70 eV). Elemental analyses are conducted by Robertson Microlit Labs, Madison NJ.


All compounds displayed NMR spectra, LRMS and either elemental analysis or HRMS
10 consistant with assigned structures.

List of Abbreviations and Acronyms:

	AcOH	acetic acid
	anh	anhydrous
	BOC	<i>tert</i> -butoxycarbonyl
15	conc	concentrated
	dec	decomposition
	DMPU	1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone
	DMF	<i>N,N</i> -dimethylformamide
	DMSO	dimethylsulfoxide
20	DPPA	diphenylphosphoryl azide
	EtOAc	ethyl acetate
	EtOH	ethanol (100%)
	Et ₂ O	diethyl ether
	Et ₃ N	triethylamine
25	<i>m</i> -CPBA	3-chloroperoxybenzoic acid
	MeOH	methanol
	pet. ether	petroleum ether (boiling range 30-60 °C)
	THF	tetrahydrofuran
	TFA	trifluoroacetic acid
30	Tf	trifluoromethanesulfonyl

A. General Methods for Synthesis of Substituted Anilines**A1. Synthesis of 2,5-Dioxopyrrolidinylanilines**


- Step 1. 4-*tert*-Butyl-1-(2,5-dioxo-1-pyrrolidinyl)-2-nitrobenzene:** To a solution of 4-*tert*-butyl-2-nitroaniline (1.04 g, 5.35 mmol) in xylene (25 mL) was added succinic anhydride (0.0535 g, 5.35 mmol) and triethylamine (0.75 mL, 5.35 mmol). The reaction mixture was heated at the reflux temp. for 24 h, cooled to room temp. and diluted with Et₂O (25 mL). The resulting mixture was sequentially washed with a 10% HCl solution (50 mL), a saturated NH₄Cl solution (50 mL) and a saturated NaCl solution (50 mL), dried (MgSO₄), and concentrated under reduced pressure. The residue was purified by flash chromatography (60% EtOAc/40% hexane) to yield the succinimide as a yellow solid (1.2 g, 86%): mp 135-138 °C; ¹H NMR (CHCl₃) δ 1.38 (s, 9H), 2.94-2.96 (m, 4H), 7.29-7.31 (m, 1H), 7.74-7.78 (m, 1H), 8.18-8.19 (m, 1H).




- Step 2. 5-*tert*-Butyl-2-(2,5-dioxo-1-pyrrolidinyl)aniline:** To a solution of 4-*tert*-butyl-1-(2,5-dioxo-1-pyrrolidinyl)-2-nitrobenzene (1.1 g, 4.2 mmol) in EtOAc (25 mL) was added a 10% Pd/C (0.1 g). The resulting slurry was placed under a H₂ atmosphere using 3 cycles of an evacuate-quench protocol and was allowed to stir under a H₂ atmosphere for 8 h. The reaction mixture was filtered through a pad of Celite® and the residue was washed with CHCl₃. The combined filtrate was concentrated under reduced pressure to yield the desired aniline as an off-white solid (0.75 g, 78%): mp 208-211 °C; ¹H-NMR

(DMSO- d_6) δ 1.23 (s, 9H), 2.62-2.76 (m, 4H), 5.10 (br s, 2H), 6.52-6.56 (m, 1H), 6.67-6.70 (m, 2H).

A2. General Method for the Synthesis of Tetrahydrofuranyloxyanilines




- 5 **Step 1.4-*tert*-Butyl-1-(3-tetrahydrofuranyloxy)-2-nitrobenzene:** To a solution of 4-*tert*-butyl-2-nitrophenol (1.05 g, 5.4 mmol) in anhyd THF (25 mL) was added 3-hydroxytetrahydrofuran (0.47 g, 5.4 mmol) and triphenylphosphine (1.55 g, 5.9 mmol) followed by diethyl azodicarboxylate (0.93 mL, 5.9 mmol) and the mixture was allowed to stir at room temp. for 4 h. The resulting mixture was diluted with Et₂O (50 mL) and washed with a saturated NH₄Cl solution (50 mL) and a saturated NaCl solution (50 mL), dried (MgSO₄), and concentrated under reduced pressure. The residue was purified by flash chromatography (30% EtOAc/70% hexane) to yield the desired ether as a yellow solid (1.3 g, 91%): ¹H-NMR (CHCl₃) δ 1.30 (s, 9H), 2.18-2.24 (m, 2H), 3.91-4.09 (m, 4H), 5.00-5.02 (m, 1H), 6.93 (d, J =8.8 Hz, 1H), 7.52 (dd, J =2.6, 8.8 Hz, 1H), 7.81 (d, J =2.6 Hz, 1H).
- 10
- 15




- Step 2.5-*tert*-Butyl-2-(3-tetrahydrofuranyloxy)aniline:** To a solution of 4-*tert*-butyl-1-(3-tetrahydrofuranyloxy)-2-nitrobenzene (1.17 g, 4.4 mmol) in EtOAc (25 mL) was added 10% Pd/C (0.1). The resulting slurry was placed under a H₂ atmosphere using 3 cycles of an evacuate-quench protocol and was allowed to stir under a H₂ atmosphere for
- 20

8 h. The reaction mixture was filtered through a pad of Celite® and washed with CHCl₃. The combined filtrate was concentrated under reduced pressure to yield of the desired aniline as a yellow solid (0.89 g, 86%): mp 79-82 °C; ¹H-NMR (CHCl₃) δ 1.30 (s, 9H), 2.16-2.20 (m, 2H), 3.78 (br s, 2H), 3.85-4.10 (m, 4H), 4.90 (m, 1H), 6.65-6.82 (m, 3H).

5 A3. General Method for the Synthesis of Trifluoromethanesulfonylanilines



Step 1. 2-Methoxy-5-(fluorosulfonyl)acetanilide: Acetic anhydride (0.90 mL, 9.6 mmol) was added to a solution of 4-methoxymetanilyl fluoride (1.0 g, 4.8 mmol) in pyridine (15 mL). After being stirred at room temp. for 4 h, the reaction mixture was concentrated under reduced pressure. The resulting residue was dissolved in CH₂Cl₂ (25 mL), washed with a saturated NaHCO₃ solution (25 mL), dried (Na₂SO₄), and concentrated under reduced pressure to give a foam which was triturated with a Et₂O/hexane solution to provide the title compound (0.85 g): ¹H-NMR (CDCl₃) δ 2.13 (s, 3H), 3.98 (s, 3H), 7.36 (d, J=8.5 Hz, 1H), 7.82 (dd, J=2.6, 8.8 Hz, 1H), 8.79 (d, J=2.2 Hz, 1H), 9.62 (br s, 1H).




Step 2. 2-Methoxy-5-(trifluoromethanesulfonyl)acetanilide: To an ice-cooled suspension of tris(dimethylamino)sulfonium difluorotrimethylsiliconate (0.094 g, 0.34 mmol) in THF (4 mL) was added a solution of (trifluoromethyl)trimethylsilane (1.0 mL, 6.88 mmol) in THF (3 mL) followed by a solution of 2-methoxy-5-(fluorosulfonyl)acetanilide (0.85 g, 3.44 mmol) in THF (3 mL). The reaction mixture was stirred for 2 h on an ice bath, then was allowed to warm to room temp. and was then concentrated under reduced pressure. The resulting residue was dissolved in CH₂Cl₂ (25 mL), washed with water (25 mL), dried (Na₂SO₄), and concentrated under reduced pressure. The resulting material was purified by flash chromatography (3% MeOH/97%

CH₂Cl₂) to provide the title compound as a white solid (0.62 g): ¹H-NMR (CDCl₃) δ 2.13 (s, 3H) 4.00 (s, 3H), 7.42 (d, *J*=8.8 Hz, 1H), 7.81 (dd, *J*=2.6, 8.8 Hz, 1H), 8.80 (d, *J*=2.2 Hz, 1H), 9.64 (br s, 1H); FAB-MS *m/z* 298 ((*M*+1)⁺).



- 5 **Step 3.2-Methoxy-5-(trifluoromethanesulfonyl)aniline:** A solution of 2-methoxy-5-(trifluoromethanesulfonyl)acetanilide (0.517 g, 1.74 mmol) in EtOH (5 mL) and a 1 N HCl solution (5 mL) was heated at the reflux temp. for 4 h and the resulting mixture was concentrated under reduced pressure. The residue was dissolved in CH₂Cl₂ (30 mL), washed with water (30 mL), dried (Na₂SO₄), and concentrated under reduced pressure to
- 10 afford the title compound as a gum (0.33 g): ¹H-NMR (CDCl₃) δ 3.90 (s, 3H) 5.57 (br s, 2H), 7.11-7.27 (m, 3H); FAB-MS *m/z* 256 ((*M*+1)⁺). This material was used in urea formation without further purification.


A4. General Method for Aryl Amine Formation via Phenol Nitration Followed by Ether Formation and Reduction




15

- Step 1.2-Nitro-5-tert-butylphenol:** A mixture of fuming nitric acid (3.24 g, 77.1 mmol) in glacial HOAc (10 mL) was added dropwise to a solution of *m*-tert-butylphenol (11.58 g, 77.1 mmol) in glacial HOAc (15 mL) at 0 °C. The mixture was allowed to stir at 0 °C for 15 min then warmed to room temp. After 1 h the mixture was poured into ice water
- 20 (100 mL) and extracted with Et₂O (2 x 50 mL). The organic layer was washed with a saturated NaCl solution (100 mL), dried (MgSO₄) and concentrated *in vacuo*. The residue was purified by flash chromatography (30% EtOAc/70% hexane) to give the desired phenol (4.60 g, 31%): ¹H-NMR (DMSO-d₆) δ 1.23 (s, 9H), 7.00 (dd, *J*=1.84, 8.83 Hz, 1H), 7.07 (d, *J*=1.84 Hz, 1H), 7.82 (d, *J*=8.83 Hz, 1H), 10.74 (s, 1H).

33




- Step 2. 2-Nitro-5-*tert*-butylanisole: A slurry of 2-nitro-5-*tert*-butylphenol (3.68 g, 18.9 mmol) and K₂CO₃ (3.26 g, 23.6 mmol) in anhyd DMF (100 mL) was stirred at room temp with stirring for 15 min then treated with iodomethane (2.80 g, 19.8 mmol) via syringe. The reaction was allowed to stir at room temp for 18 h., then was treated with water (100 mL) and extracted with EtOAc (2 x 100 mL). The combined organic layers were washed with a saturated NaCl solution (50 mL), dried (MgSO₄) and concentrated *in vacuo* to give the desired ether (3.95 g, 100%): ¹H-NMR (DMSO-d₆) δ 1.29 (s, 9H), 3.92 (s, 3H), 7.10 (dd, *J*=1.84, 8.46 Hz, 1H), 7.22 (d, *J*=1.84 Hz, 1H), 7.79 (d, *J*=8.46 Hz, 1H).
- 10 This material was used in the next step without further purification.




- Step 3. 4-*tert*-Butyl-2-methoxyaniline: A solution of 2-nitro-5-*tert*-butylanisole (3.95 g, 18.9 mmol) in MeOH (65 mL) and added to a flask containing 10% Pd/C in MeOH (0.400 g), then placed under a H₂ atmosphere (balloon). The reaction was allowed to stir for 18 h at room temp, then filtered through a pad of Celite® and concentrated *in vacuo* to afford the desired product as a dark sticky solid (3.40 g, 99%): ¹H-NMR (DMSO-d₆) δ 1.20 (s, 9H), 3.72 (s, 3H), 4.43 (br s, 2H), 6.51 (d, *J*=8.09 Hz, 1H), 6.64 (dd, *J*=2.21, 8.09 Hz, 1H), 6.76 (d, *J*=2.21 Hz, 1H).
- 15

- 20 A5. General Method for Aryl Amine Formation via Carboxylic Acid Esterification Followed by Reduction



Step 1. Methyl 2-Nitro-4-(trifluoromethyl)benzoate: To a solution of 2-nitro-4-(trifluoromethyl)benzoic acid (4.0 g, 17.0 mmol) in MeOH (150 mL) at room temp was added conc H₂SO₄ (2.5 mL). The mixture was heated at the reflux temp for 24 h., cooled to room temp and concentrated in vacuo. The residue was diluted with water (100 mL) and extracted with EtOAc (2 x 100 mL). The combined organic layers were washed with a saturated NaCl solution, dried (MgSO₄), concentrated *in vacuo*. The residue was purified by flash chromatography (14% EtOAc/86% hexane) to give the desired ester as a pale yellow oil (4.17 g, 98%): ¹H-NMR (DMSO-d₆) δ 3.87 (s, 3H), 8.09 (d, *J*=7.72 Hz, 1H), 8.25 (dd, *J*=1.11, 8.09 Hz, 1H), 8.48 (d, *J*=1.11 Hz, 1H).




10

Step 2. Methyl 2-Amino-4-(trifluoromethyl)benzoate: A solution of methyl 2-nitro-4-(trifluoromethyl)benzoate (3.90 g, 15.7 mmol) in EtOAc (100 mL) and added to a flask containing 10% Pd/C (0.400 mg) in EtOAc (10 mL), then placed under a H₂ atmosphere (balloon). The reaction was allowed to stir for 18 h at room temp, then was filtered through Celite® and concentrated *in vacuo* to afford the desired product as a white crystalline solid (3.20 g, 93%): ¹H-NMR (DMSO-d₆) δ 3.79 (s, 3H), 6.75 (dd, *J*=1.84, 8.46 Hz, 1H), 6.96 (br s, 2H), 7.11 (d, *J*=0.73 Hz, 1H), 7.83 (d, *J*=8.09 Hz, 1H).

15

A6. General Method for Aryl Amine Formation via Ether Formation Followed
Ester Saponification, Curtius Rearrangement, and Carbamate Deprotection


20




Step 1. Methyl 3-Methoxy-2-naphthoate: A slurry of methyl 3-hydroxy-2-naphthoate (10.1 g, 50.1 mmol) and K₂CO₃ (7.96 g, 57.6 mmol) in DMF (200 mL) was stirred at room temp for 15 min, then treated with iodomethane (3.43 mL, 55.1 mmol). The mixture was allowed to stir at room temp overnight, then was treated with water (200 mL). The

25

resulting mixture was extracted with EtOAc (2 x 200 mL). The combined organic layers were washed with a saturated NaCl solution (100 mL), dried (MgSO_4), concentrated *in vacuo* (approximately 0.4 mmHg overnight) to give the desired ether as an amber oil (10.30 g): $^1\text{H-NMR}$ (DMSO-d_6) δ 2.70 (s, 3H), 2.85 (s, 3H), 7.38 (app t, $J=8.09$ Hz, 1H), 7.44 (s, 1H), 7.53 (app t, $J=8.09$ Hz, 1H), 7.84 (d, $J=8.09$ Hz, 1H), 7.90 (s, 1H), 8.21 (s, 1H).




Step 2. 3-Methoxy-2-naphthoic Acid: A solution of methyl 3-methoxy-2-naphthoate (6.28 g, 29.10 mmol) and water (10 mL) in MeOH (100 mL) at room temp was treated with a 1 N NaOH solution (33.4 mL, 33.4 mmol). The mixture was heated at the reflux temp for 3 h, cooling to room temp, and made acidic with a 10% citric acid solution. The resulting solution was extracted with EtOAc (2 x 100 mL). The combined organic layers were washed with a saturated NaCl solution, dried (MgSO_4) and concentrated *in vacuo*. The residue was triturated with hexanes and washed several times with hexanes to give the desired carboxylic acid as a white crystalline solid (5.40 g, 92%): $^1\text{H-NMR}$ (DMSO-d_6) δ 3.88 (s, 3H), 7.34-7.41 (m, 2H), 7.49-7.54 (m, 1H), 7.83 (d, $J=8.09$ Hz, 1H), 7.91 (d, $J=8.09$ Hz, 1H), 8.19 (s, 1H), 12.83 (br s, 1H).




Step 3. 2-(N-(Carbobenzyloxy)amino)-3-methoxynaphthalene: A solution of 3-methoxy-2-naphthoic acid (3.36 g, 16.6 mmol) and Et_3N (2.59 mL, 18.6 mmol) in anhydrous toluene (70 mL) was stirred at room temp. for 15 min., then treated with a solution of diphenylphosphoryl azide (5.12 g, 18.6 mmol) in toluene (10 mL) *via* pipette. The resulting mixture was heated at 80 °C for 2 h. After cooling the mixture to room temp. benzyl alcohol (2.06 mL, 20 mmol) was added *via* syringe. The mixture was then warmed to 80 °C overnight. The resulting mixture was cooled to room temp., quenched with a

10% citric acid solution, and extracted with EtOAc (2 x 100 mL). The combined organic layers were washed with a saturated NaCl solution, dried (MgSO₄), and concentrated *in vacuo*. The residue was purified by flash chromatography (14% EtOAc/86% hexane) to give the benzyl carbamate as a pale yellow oil (5.1 g, 100%): ¹H-NMR (DMSO-d₆) δ 3.89 (s, 3H), 5.17 (s, 2H), 7.27-7.44 (m, 8H), 7.72-7.75 (m, 2H), 8.20 (s, 1H), 8.76 (s, 1H).




Step 4.2-Amino-3-methoxynaphthalene: A slurry of 2-(*N*-(carbobenzyloxy)amino-3-methoxynaphthalene (5.0 g, 16.3 mmol) and 10% Pd/C (0.5 g) in EtOAc (70mL) was maintained under a H₂ atmospheric (balloon) at room temp. overnight. The resulting mixture was filtered through Celite® and concentrated *in vacuo* to give the desired amine as a pale pink powder (2.40 g, 85%): ¹H-NMR (DMSO-d₆) δ 3.86 (s, 3H), 6.86 (s, 2H), 7.04-7.16 (m, 2H), 7.43 (d, *J*=8.0 Hz, 1H), 7.56 (d, *J*=8.0 Hz, 1H); EI-MS *m/z* 173 (M⁺).


A7. General Method for the Synthesis of Aryl Amines via Metal-Mediated Cross Coupling Followed by Reduction



Step 1.5-*tert*-Butyl-2-(trifluoromethanesulfonyl)oxy-1-nitrobenzene: To an ice cold solution of 4-*tert*-butyl-2-nitrophenol (6.14 g, 31.5 mmol) and pyridine (10 mL, 125 mmol) in CH₂Cl₂ (50 mL) was slowly added trifluoromethanesulfonic anhydride (10 g, 35.5 mmol) via syringe. The reaction mixture was stirred for 15 min, then allowed to warm up to room temp. and diluted with CH₂Cl₂ (100 mL). The resulting mixture was sequentially washed with a 1M NaOH solution (3 x 100 mL), and a 1M HCl solution (3 x 100 mL), dried (MgSO₄), and concentrated under reduced pressure to afford the title compound (8.68 g, 84%): ¹H-NMR (CDCl₃) δ 1.39 (s, 9H), 7.30-8.20 (m, 3H).




Step 2. **5-*tert*-Butyl-2-(3-fluorophenyl)-1-nitrobenzene:** A mixture of 3-fluorobenzeneboronic acid (3.80 g, 27.5 mmol), KBr (2.43 g, 20.4 mmol), K_3PO_4 (6.1 g, 28.8 mmol), and $Pd(PPh_3)_4$ (1.0 g, 0.9 mmol) was added to a solution of 5-*tert*-butyl-2-(trifluoromethanesulfonyl)oxy-1-nitrobenzene (6.0 g, 18.4 mmol) in dioxane (100 mL). The reaction mixture was heated at 80 °C for 24 h, at which time TLC indicated complete reaction. The reaction mixture was treated with a saturated NH_4Cl solution (50 mL) and extracted EtOAc (3 x 100 mL). The combined organic layers were dried ($MgSO_4$) and concentrated under reduced pressure. The residue was purified by flash chromatography (3% EtOAc/97% hexane) to give the title compound (4.07 g, 81%): 1H -NMR ($CDCl_3$) δ 1.40 (s, 9H), 6.90-7.90 (m, 7H).




Step 3. **5-*tert*-Butyl-2-(3-fluorophenyl)aniline:** To a solution of 5-*tert*-butyl-2-(3-fluorophenyl)-1-nitrobenzene (3.5 g, 12.8 mmol) and EtOH (24 mL) in EtOAc (96 mL) was added 5% Pd/C (0.350 g) and the resulting slurry was stirred under a H_2 atmosphere for 24 h, at which time TLC indicated complete consumption of starting material. The reaction mixture was filtered through a pad of Celite® to give the desired product (2.2 g, 72%): 1H -NMR ($CDCl_3$) δ 1.35 (s, 9H), 3.80 (br s, 2H), 6.90-7.50 (m, 7H).

20 A8. General Method for the Synthesis of Nitroanilines


38



Step 1.4-(4-(2-Propoxycarbonylamino)phenyl)methylaniline: A solution of di-*tert*-butyl dicarbonate (2.0 g, 9.2 mmol) and 4,4'-methylenedianiline (1.8g, 9.2 mmol) in DMF (100 mL) was heated at the reflux temp. for 2 h, then cooled to room temp. This mixture was diluted with EtOAc (200 mL) sequentially washed with a saturated NH_4Cl (200 mL) and a saturated NaCl solution (100 mL), and dried (MgSO_4). The residue was purified by flash chromatography (30% EtOAc/70% hexane) to give the desired carbamate (1.3 g, 48%): $^1\text{H-NMR}$ (CDCl_3) δ 1.51 (s, 9H), 3.82 (s, 2H), 6.60-7.20 (m, 8H).




Step 2.4-(4-(2-Propoxycarbonylamino)phenyl)methyl-1-nitrobenzene: To an ice cold solution of 4-(4-(2-propoxycarbonylamino)phenyl)methylaniline (1.05 g, 3.5 mmol) in CH_2Cl_2 (15 mL) was added *m*-CPBA (1.2 g, 7.0 mmol). The reaction mixture was slowly allowed to warm to room temp. and was stirred for 45 min, at which time TLC indicated disappearance of starting material. The resulting mixture was diluted with EtOAc (50 mL), sequentially washed with a 1M NaOH solution (50 mL) and a saturated NaCl solution (50 mL), and dried (MgSO_4). The residue was purified by flash chromatography (20% EtOAc/80% hexane) to give the desired nitrobenzene (0.920 g): FAB-MS m/z 328 (M^+).




Step 3.4-(4-Nitrophenyl)methylaniline: To a solution of 4-(4-(2-propoxycarbonylamino)phenyl)methyl-1-nitrobenzene (0.920 g, 2.8 mmol) in dioxane (10 mL) was added a conc. HCl solution (4.0 mL) and the resulting mixture was heated at 80 °C for 1 h at which time TLC indicated disappearance of starting material. The reaction mixture was cooled to room temp. The resulting mixture was diluted with EtOAc (50 mL), then washed with a 1M NaOH solution (3 x 50 mL), and dried (MgSO_4) to give the desired aniline (0.570 mg, 89%): $^1\text{H-NMR}$ (CDCl_3) δ 3.70 (br s, 2H), 3.97 (s,

2H), 6.65 (d, $J=8.5$ Hz, 2H), 6.95 (d, $J=8.5$ Hz, 2H), 7.32 (d, $J=8.8$ Hz, 2H), 8.10 (d, $J=8.8$ Hz, 2H).


5 A9. General Method for Synthesis of Aryl Anilines via Alkylation of a Nitrophenol Followed by Reduction



10 Step 1.4-(α -Bromoacetyl)morpholine: To an ice cold solution of morpholine (2.17 g, 24.9 mmol) and diisopropylethylamine (3.21 g, 24.9 mmol) in CH_2Cl_2 (70 mL) was added a solution of bromoacetyl bromide (5.05 g, 25 mmole) in CH_2Cl_2 (8 mL) via syringe. The resulting solution was kept at 0 °C for 45 min, then was allowed to warm to room temp. The reaction mixture was diluted with EtOAc (500 mL), sequentially washed with a 1M HCl solution (250 mL) and a saturated NaCl solution (250 mL), and dried (MgSO_4) to give the desired product (3.2 g, 62%): $^1\text{H-NMR}$ (DMSO-d_6) δ 3.40-3.50 (m, 4H), 3.50-3.60 (m, 4H), 4.11 (s, 2H).




15 Step 2.2-(*N*-Morpholinylcarbonyl)methoxy-5-*tert*-butyl-1-nitrobenzene: A slurry of 4-*tert*-butyl-2-nitrophenol (3.9 g, 20 mmol) and K_2CO_3 (3.31 g, 24 mmol) in DMF (75 mL) was stirred at room temp. for 15 minutes, then a solution of 4-(α -bromoacetyl)morpholine (4.16 g, 20 mmol) in DMF (10 mL) was added. The reaction
20 was allowed to stir at room temp. overnight, then was diluted with EtOAc (500 mL) and sequentially washed with a saturated NaCl solution (4 x 200 mL) and a 1M NaOH solution (400 mL). The residue was purified by flash chromatography (75% EtOAc/25% hexane) to give the nitrobenzene (2.13 g, 33%): $^1\text{H-NMR}$ (DMSO-d_6) δ 1.25 (s, 9H), 3.35-3.45 (m, 4H), 3.50-3.58 (m, 4H), 5.00 (s, 2H), 7.12 (d, $J=8.8$ Hz, 1H), 7.50-7.80 (m,
25 2H).




Step 3.2-(*N*-Morpholinylcarbonyl)methoxy-5-*tert*-butylaniline: To a solution of 2-(*N*-morpholinylcarbonyl)methoxy-5-*tert*-butyl-1-nitrobenzene (2.13 g, 6.6 mmol) and EtOH (10 mL) in EtOAc (40 mL) was added 5% Pd/C (0.215 g). The resulting slurry was stirred under a H₂ atmosphere for 6 h, at which time TLC indicated complete consumption of starting material. The reaction mixture was filtered through a pad of Celite® to give the desired product (1.9 g, 98%): ¹H-NMR (DMSO-*d*₆) δ 1.18 (s, 9H), 3.40-3.50 (m, 4H), 3.50-3.60 (m, 4H), 4.67 (br s, 2H), 4.69 (s, 2H), 6.40-6.70 (m, 3H).


10 A10. General Method for Aryl Amine Formation via Nitrophenol Alkylation Followed by Reduction



Step 1.5-*tert*-Butyl-2-(2-hydroxyethoxy)-1-nitrobenzene: A solution of 4-*tert*-butyl-2-nitrophenol (30 g, 0.15 mol) and tetra-*n*-butylammonium fluoride (0.771 g, 3.0 mmol) in ethylene carbonate (10.24 mL, 0.15 mol) was heated at 150 °C for 18 h, then cooled to room temp. and separated between water (50 mL) and CH₂Cl₂ (50 mL). The organic layer was dried (MgSO₄) and concentrated under reduced pressure. The residue was purified by column chromatography (20% EtOAc/80% hexane) to afford the desired product as a brown oil (35.1 g, 90%): ¹H-NMR (DMSO-*d*₆) δ 1.25 (s, 9H), 3.66-3.69 (m, 2H), 4.10-4.14 (t, *J*=5.0 Hz, 2H), 4.85 (t, *J*=5.0 Hz, 1H), 7.27 (d, *J*=8.8 Hz, 1H), 7.60-7.64 (m, 1H), 7.75 (d, *J*=2.6 Hz, 1H).




Step 2. 5-tert-Butyl-2-(2-tert-butoxycarbonyloxy)ethoxy)-1-nitrobenzene: A solution of 5-tert-butyl-2-(2-hydroxyethoxy)-1-nitrobenzene (0.401 g, 1.68 mmol), di-tert-butyl dicarbonate (0.46 mL, 2.0 mmol) and dimethylaminopyridine (0.006 g, 0.05 mmol) in CH₂Cl₂ (15 mL) was stirred at room temp. for 30 min, at which time TLC indicated consumption of starting material. The resulting mixture was washed with water (20 mL), dried (MgSO₄) and concentrated under reduced pressure. The residue was purified by column chromatography (3% MeOH/97% CH₂Cl₂) to give the desired product as a yellow oil (0.291 g, 51%): ¹H-NMR (DMSO-d₆) δ 1.25 (s, 9H), 1.38 (s, 9H), 4.31 (br s, 4H), 7.27 (d, J=9.2 Hz, 1H) 7.64 (dd, J=2.6, 8.8 Hz, 1H) 7.77 (d, J=2.6 Hz, 1H).



Step 3. 5-tert-Butyl-2-(2-tert-butoxycarbonyloxy)ethoxy)aniline: To a mixture of 5-tert-butyl-2-(2-tert-butoxycarbonyloxy)ethoxy)-1-nitrobenzene (0.290 g, 0.86 mmol) and 5% Pd/C (0.058 g) in MeOH (2 mL) was ammonium formate (0.216 g, 3.42 mmol), and the resulting mixture was stirred at room temp. for 12 h, then was filtered through a pad of Celite® with the aid of EtOH. The filtrate was concentrated under reduced pressure and the residue was purified by column chromatography (2% MeOH/98% CH₂Cl₂) to give the desired product as a pale yellow oil (0.232 g, 87%): TLC (20% EtOAc/80% hexane) R_f 0.63; ¹H-NMR (DMSO-d₆) δ 1.17 (s, 9H), 1.39 (s, 9H), 4.03-4.06 (m, 2H), 4.30-4.31 (m, 2H), 4.54 (br s, 2H), 6.47 (dd, J=2.2, 8.1 Hz, 1H) 6.64-6.67 (m, 2H).

A11. General Method for Substituted Aniline Formation via Hydrogenation of a Nitroarene


42



4-(4-Pyridinylmethyl)aniline: To a solution of 4-(4-nitrobenzyl)pyridine (7.0 g, 32.68 mmol) in EtOH (200 mL) was added 10% Pd/C (0.7 g) and the resulting slurry was shaken under a H₂ atmosphere (50 psi) using a Parr shaker. After 1 h, TLC and ¹H-NMR of an aliquot indicated complete reaction. The mixture was filtered through a short pad of Celite®. The filtrate was concentrated *in vacuo* to afford a white solid (5.4 g, 90%): ¹H-NMR (DMSO-d₆) δ 3.74 (s, 2H), 4.91 (br s, 2H), 6.48 (d, *J*=8.46 Hz, 2H), 6.86 (d, *J*=8.09 Hz, 2H), 7.16 (d, *J*=5.88 Hz, 2H), 8.40 (d, *J*=5.88 Hz, 2H); EI-MS *m/z* 184 (M⁺). This material was used in urea formation reactions without further purification.

10

A12. General Method for Substituted Aniline Formation via Dissolving Metal Reduction of a Nitroarene




4-(2-Pyridinylthio)aniline: To a solution of 4-(2-pyridinylthio)-1-nitrobenzene (Menai ST 3355A; 0.220 g, 0.95 mmol) and H₂O (0.5 mL) in AcOH (5 mL) was added iron powder (0.317 g, 5.68 mmol) and the resulting slurry stirred for 16 h at room temp. The reaction mixture was diluted with EtOAc (75 mL) and H₂O (50 mL), basified to pH 10 by adding solid K₂CO₃ in portions (*Caution*: foaming). The organic layer was washed with a saturated NaCl solution, dried (MgSO₄), concentrated *in vacuo*. The residual solid was purified by MPLC (30% EtOAc/70% hexane) to give the desired product as a thick oil (0.135 g, 70%): TLC (30% EtOAc/70% hexanes) R_f 0.20.


20

A13a. General Method for Substituted Aniline Formation via Nitroarene Formation Through Nucleophilic Aromatic Substitution, Followed by Reduction

25




- Step 1. 1-Methoxy-4-(4-nitrophenoxy)benzene: To a suspension of NaH (95%, 1.50 g, 59 mmol) in DMF (100 mL) at room temp. was added dropwise a solution of 4-methoxyphenol (7.39 g, 59 mmol) in DMF (50 mL). The reaction was stirred 1 h, then a solution of 1-fluoro-4-nitrobenzene (7.0 g, 49 mmol) in DMF (50 mL) was added dropwise to form a dark green solution. The reaction was heated at 95 °C overnight, then cooled to room temp., quenched with H₂O, and concentrated *in vacuo*. The residue was partitioned between EtOAc (200 mL) and H₂O (200 mL). The organic layer was sequentially washed with H₂O (2 x 200 mL), a saturated NaHCO₃ solution (200 mL), and a saturated NaCl solution (200 mL), dried (Na₂SO₄), and concentrated *in vacuo*. The residue was triturated (Et₂O/hexane) to afford 1-methoxy-4-(4-nitrophenoxy)benzene (12.2 g, 100%): ¹H-NMR (CDCl₃) δ 3.83 (s, 3H), 6.93-7.04 (m, 6H), 8.18 (d, J=9.2 Hz, 2H); EI-MS *m/z* 245 (M⁺).




- Step 2. 4-(4-Methoxyphenoxy)aniline: To a solution of 1-methoxy-4-(4-nitrophenoxy)benzene (12.0 g, 49 mmol) in EtOAc (250 mL) was added 5% Pt/C (1.5 g) and the resulting slurry was shaken under a H₂ atmosphere (50 psi) for 18 h. The reaction mixture was filtered through a pad of Celite® with the aid of EtOAc and concentrated *in vacuo* to give an oil which slowly solidified (10.6 g, 100%): ¹H-NMR (CDCl₃) δ 3.54 (br s, 2H), 3.78 (s, 3H), 6.65 (d, J=8.8 Hz, 2H), 6.79-6.92 (m, 6H); EI-MS *m/z* 215 (M⁺).

A13b. General Method for Substituted Aniline Formation via Nitroarene Formation Through Nucleophilic Aromatic Substitution, Followed by Reduction




- Step 1. 3-(Trifluoromethyl)-4-(4-pyridinylthio)nitrobenzene: A solution of 4-mercaptopyridine (2.8 g, 24 mmoles), 2-fluoro-5-nitrobenzotrifluoride (5 g, 23.5 mmoles), and potassium carbonate (6.1 g, 44.3 mmoles) in anhydrous DMF (80 mL) was

stirred at room temperature and under argon overnight. TLC showed complete reaction. The mixture was diluted with Et₂O (100 mL) and water (100 mL) and the aqueous layer was back-extracted with Et₂O (2 x 100 mL). The organic layers were washed with a saturated NaCl solution (100 mL), dried (MgSO₄), and concentrated under reduced pressure. The solid residue was triturated with Et₂O to afford the desired product as a tan solid (3.8 g, 54%): TLC (30% EtOAc/70% hexane) R_f 0.06; ¹H-NMR (DMSO-d₆) δ 7.33 (dd, J=1.2, 4.2 Hz, 2H), 7.78 (d, J=8.7 Hz, 1H), 8.46 (dd, J=2.4, 8.7Hz, 1H), 8.54-8.56 (m, 3H).




Step 2. 3-(Trifluoromethyl)-4-(4-pyridinylthio)aniline: A slurry of 3-trifluoromethyl-4-(4-pyridinylthio)nitrobenzene (3.8 g, 12.7 mmol), iron powder (4.0 g, 71.6 mmol), acetic acid (100 mL), and water (1 mL) were stirred at room temp. for 4 h. The mixture was diluted with Et₂O (100 mL) and water (100 mL). The aqueous phase was adjusted to pH 4 with a 4 N NaOH solution. The combined organic layers were washed with a saturated NaCl solution (100 mL), dried (MgSO₄), and concentrated under reduced pressure. The residue was filtered through a pad of silica (gradient from 50% EtOAc/50% hexane to 60% EtOAc/40% hexane) to afford the desired product (3.3 g): TLC (50% EtOAc/50% hexane) R_f 0.10; ¹H-NMR (DMSO-d₆) δ 6.21 (s, 2H), 6.84-6.87 (m, 3H), 7.10 (d, J=2.4 Hz, 1H), 7.39 (d, J=8.4 Hz, 1H), 8.29 (d, J=6.3 Hz, 2H).

A13c. General Method for Substituted Aniline Formation via Nitroarene Formation Through Nucleophilic Aromatic Substitution, Followed by Reduction




Step 1. 4-(2-(4-Phenyl)thiazolyl)thio-1-nitrobenzene: A solution of 2-mercapto-4-phenylthiazole (4.0 g, 20.7 mmoles) in DMF (40 mL) was treated with 1-fluoro-4-

nitrobenzene (2.3 mL, 21.7 mmol) followed by K_2CO_3 (3.18 g, 23 mmol), and the mixture was heated at approximately 65 °C overnight. The reaction mixture was then diluted with EtOAc (100 mL), sequentially washed with water (100 mL) and a saturated NaCl solution (100 mL), dried ($MgSO_4$) and concentrated under reduced pressure. The solid residue was triturated with a Et_2O /hexane solution to afford the desired product (6.1 g): TLC (25% EtOAc/75% hexane) R_f 0.49; 1H -NMR ($CDCl_3$) δ 7.35-7.47 (m, 3H), 7.58-7.63 (m, 3H), 7.90 (d, $J=6.9$ Hz, 2H), 8.19 (d, $J=9.0$ Hz, 2H).




Step 2. 4-(2-(4-Phenyl)thiazolyl)thioaniline: 4-(2-(4-Phenyl)thiazolyl)thio-1-nitrobenzene was reduced in a manner analogous to that used in the preparation of 3-(trifluoromethyl)-4-(4-pyridinylthio)aniline: TLC (25% EtOAc/75% hexane) R_f 0.18; 1H -NMR ($CDCl_3$) δ 3.89 (br s, 2H), 6.72-6.77 (m, 2H), 7.26-7.53 (m, 6H), 7.85-7.89 (m, 2H).

A13d. General Method for Substituted Aniline Formation via Nitroarene Formation Through Nucleophilic Aromatic Substitution, Followed by Reduction



Step 1. 4-(6-Methyl-3-pyridinyloxy)-1-nitrobenzene: To a solution of 5-hydroxy-2-methylpyridine (5.0 g, 45.8 mmol) and 1-fluoro-4-nitrobenzene (6.5 g, 45.8 mmol) in anhydrous DMF (50 mL) was added K_2CO_3 (13.0 g, 91.6 mmol) in one portion. The mixture was heated at the reflux temp. with stirring for 18 h and then allowed to cool to room temp. The resulting mixture was poured into water (200 mL) and extracted with EtOAc (3 x 150 mL). The combined organics were sequentially washed with water (3 x 100 mL) and a saturated NaCl solution (2 x 100 mL), dried (Na_2SO_4), and concentrated *in vacuo* to


afford the desired product (8.7 g, 83%). The this material was carried to the next step without further purification.



Step 2. 4-(6-Methyl-3-pyridinyloxy)aniline: A solution of 4-(6-methyl-3-pyridinyloxy)-1-nitrobenzene (4.0 g, 17.3 mmol) in EtOAc (150 mL) was added to 10% Pd/C (0.500 g, 0.47 mmol) and the resulting mixture was placed under a H₂ atmosphere (balloon) and was allowed to stir for 18 h at room temp. The mixture was then filtered through a pad of Celite® and concentrated *in vacuo* to afford the desired product as a tan solid (3.2 g, 92%): EI-MS *m/z* 200 (M⁺).


10

A13e. General Method for Substituted Aniline Formation via Nitroarene Formation Through Nucleophilic Aromatic Substitution, Followed by Reduction



Step 1. 4-(3,4-Dimethoxyphenoxy)-1-nitrobenzene: To a solution of 3,4-dimethoxyphenol (1.0 g, 6.4 mmol) and 1-fluoro-4-nitrobenzene (700 μ L, 6.4 mmol) in anhyd DMF (20 mL) was added K₂CO₃ (1.8 g, 12.9 mmol) in one portion. The mixture was heated at the reflux temp with stirring for 18 h and then allowed to cool to room temp. The mixture was then poured into water (100 mL) and extracted with EtOAc (3 x 100 mL). The combined organics were sequentially washed with water (3 x 50 mL) and a saturated NaCl solution (2 x 50 mL), dried (Na₂SO₄), and concentrated *in vacuo* to afford the desired product (0.8 g, 54%). The crude product was carried to the next step without further purification.

20




Step 2. 4-(3,4-Dimethoxyphenoxy)aniline: A solution of 4-(3,4-dimethoxy-phenoxy)-1-nitrobenzene (0.8 g, 3.2 mmol) in EtOAc (50 mL) was added to 10% Pd/C (0.100 g) and the resulting mixture was placed under a H₂ atmosphere (balloon) and was allowed to


25

stir for 18 h at room temp. The mixture was then filtered through a pad of Celite and concentrated *in vacuo* to afford the desired product as a white solid (0.6 g, 75%): EI-MS m/z 245 (M^+).

5 **A13f. General Method for Substituted Aniline Formation via Nitroarene Formation Through Nucleophilic Aromatic Substitution, Followed by Reduction**




10 Step 1. 3-(3-Pyridinyloxy)-1-nitrobenzene: To a solution of 3-hydroxypyridine (2.8 g, 29.0 mmol), 1-bromo-3-nitrobenzene (5.9 g, 29.0 mmol) and copper(I) bromide (5.0 g, 34.8 mmol) in anhyd DMF (50 mL) was added K_2CO_3 (8.0 g, 58.1 mmol) in one portion. The resulting mixture was heated at the reflux temp. with stirring for 18 h and then allowed to cool to room temp. The mixture was then poured into water (200 mL) and extracted with EtOAc (3 x 150 mL). The combined organics were sequentially washed
15 with water (3 x 100 mL) and a saturated NaCl solution (2 x 100 mL), dried (Na_2SO_4), and concentrated *in vacuo*. The resulting oil was purified by flash chromatography (30% EtOAc/70% hexane) to afford the desired product (2.0 g, 32 %). This material was used in the next step without further purification.




20 Step 2. 3-(3-Pyridinyloxy)aniline: A solution of 3-(3-pyridinyloxy)-1-nitrobenzene (2.0 g, 9.2 mmol) in EtOAc (100 mL) was added to 10% Pd/C (0.200 g) and the resulting mixture was placed under a H_2 atmosphere (balloon) and was allowed to stir for 18 h at room temp. The mixture was then filtered through a pad of Celite® and concentrated *in vacuo* to afford the desired product as a red oil (1.6 g, 94%): EI-MS m/z 186 (M^+).

25

A13g. General Method for Substituted Aniline Formation via Nitroarene Formation Through Nucleophilic Aromatic Substitution, Followed by Reduction




Step 1. 3-(5-Methyl-3-pyridinyloxy)-1-nitrobenzene: To a solution of 3-hydroxy-5-methylpyridine (5.0 g, 45.8 mmol), 1-bromo-3-nitrobenzene (12.0 g, 59.6 mmol) and copper(I) iodide (10.0 g, 73.3 mmol) in anhyd DMF (50 mL) was added K_2CO_3 (13.0 g, 91.6 mmol) in one portion. The mixture was heated at the reflux temp. with stirring for 18 h and then allowed to cool to room temp. The mixture was then poured into water (200 mL) and extracted with EtOAc (3 x 150 mL). The combined organics were sequentially washed with water (3 x 100 mL) and a saturated NaCl solution (2 x 100 mL), dried (Na_2SO_4), and concentrated *in vacuo*. The resulting oil was purified by flash chromatography (30% EtOAc/70% hexane) to afford the desired product (1.2 g, 13%).




Step 2. 3-(5-Methyl-3-pyridinyloxy)-1-nitrobenzene: A solution of 3-(5-methyl-3-pyridinyloxy)-1-nitrobenzene (1.2 g, 5.2 mmol) in EtOAc (50 mL) was added to 10% Pd/C (0.100 g) and the resulting mixture was placed under a H_2 atmosphere (balloon) and was allowed to stir for 18 h at room temp. The mixture was then filtered through a pad of Celite® and concentrated *in vacuo* to afford the desired product as a red oil (0.9 g, 86%); CI-MS m/z 201 ($(M+H)^+$).

A13h. General Method for Substituted Aniline Formation via Nitroarene Formation Through Nucleophilic Aromatic Substitution, Followed by Reduction




Step 1. 5-Nitro-2-(4-methylphenoxy)pyridine: To a solution of 2-chloro-5-nitropyridine (6.34 g, 40 mmol) in DMF (200 mL) were added 4-methylphenol (5.4 g, 50 mmol, 1.25 equiv) and K_2CO_3 (8.28 g, 60 mmol, 1.5 equiv). The mixture was stirred overnight at room temp. The resulting mixture was treated with water (600 mL) to generate a precipitate. This mixture was stirred for 1 h, and the solids were separated and

sequentially washed with a 1 N NaOH solution (25 mL), water (25 mL) and pet ether (25 mL) to give the desired product (7.05 g, 76%): mp 80-82 °C; TLC (30% EtOAc/70% pet ether) R_f 0.79; $^1\text{H-NMR}$ (DMSO- d_6) δ 2.31 (s, 3H), 7.08 (d, $J=8.46$ Hz, 2H), 7.19 (d, $J=9.20$ Hz, 1H), 7.24 (d, $J=8.09$ Hz, 2H), 8.58 (dd, $J=2.94$, 8.82 Hz, 1H), 8.99 (d, $J=2.95$ Hz, 1H); FAB-MS m/z (rel abundance) 231 ((M+H) $^+$), 100%).




Step 2. 5-Amino-2-(4-methylphenoxy)pyridine Dihydrochloride: A solution 5-nitro-2-(4-methylphenoxy)pyridine (6.94 g, 30 mmol, 1 eq) and EtOH (10 mL) in EtOAc (190 mL) was purged with argon then treated with 10% Pd/C (0.60 g). The reaction mixture was then placed under a H_2 atmosphere and was vigorously stirred for 2.5 h. The reaction mixture was filtered through a pad of Celite®. A solution of HCl in Et $_2$ O was added to the filtrate was added dropwise. The resulting precipitate was separated and washed with EtOAc to give the desired product (7.56 g, 92%): mp 208-210 °C (dec); TLC (50% EtOAc/50% pet ether) R_f 0.42; $^1\text{H-NMR}$ (DMSO- d_6) δ 2.25 (s, 3H), 6.98 (d, $J=8.45$ Hz, 2H), 7.04 (d, $J=8.82$ Hz, 1H), 7.19 (d, $J=8.09$ Hz, 2H), 8.46 (dd, $J=2.57$, 8.46 Hz, 1H), 8.63 (d, $J=2.57$ Hz, 1H); EI-MS m/z (rel abundance) (M^+ , 100%).

A13i. General Method for Substituted Aniline Formation via Nitroarene Formation Through Nucleophilic Aromatic Substitution, Followed by Reduction



Step 1. 4-(3-Thienylthio)-1-nitrobenzene: To a solution of 4-nitrothiophenol (80%pure; 1.2 g, 6.1 mmol), 3-bromothiophene (1.0 g, 6.1 mmol) and copper(II) oxide (0.5 g, 3.7 mmol) in anhydrous DMF (20 mL) was added KOH (0.3 g, 6.1 mmol), and the resulting mixture was heated at 130 °C with stirring for 42 h and then allowed to cool to room temp. The reaction mixture was then poured into a mixture of ice and a 6N HCl


solution (200 mL) and the resulting aqueous mixture was extracted with EtOAc (3 x 100 mL). The combined organic layers were sequentially washed with a 1M NaOH solution (2 x 100 mL) and a saturated NaCl solution (2 x 100 mL), dried (MgSO₄), and concentrated *in vacuo*. The residual oil was purified by MPLC (silica gel; gradient from 10% EtOAc/90% hexane to 5% EtOAc/95% hexane) to afford of the desired product (0.5 g, 34%). GC-MS *m/z* 237 (M⁺).



Step 2. 4-(3-Thienylthio)aniline: 4-(3-Thienylthio)-1-nitrobenzene was reduced to the aniline in a manner analogous to that described in Method B1.

10

A13j. General Method for Substituted Aniline Formation via Nitroarene Formation Through Nucleophilic Aromatic Substitution, Followed by Reduction




15

4-(5-Pyrimidininyloxy)aniline: 4-Aminophenol (1.0 g, 9.2 mmol) was dissolved in DMF (20 mL) then 5-bromopyrimidine (1.46 g, 9.2 mmol) and K₂CO₃ (1.9 g, 13.7 mmol) were added. The mixture was heated to 100 °C for 18 h and at 130 °C for 48 h at which GC-MS analysis indicated some remaining starting material. The reaction mixture was cooled to room temp. and diluted with water (50 mL). The resulting solution was extracted with EtOAc (100 mL). The organic layer was washed with a saturated NaCl solution (2 x 50 mL), dried (MgSO₄), and concentrated *in vacuo*. The residual solids were purified by MPLC (50% EtOAc/50% hexanes) to give the desired amine (0.650 g, 38%).


25

A13k. General Method for Substituted Aniline Formation via Nitroarene Formation Through Nucleophilic Aromatic Substitution, Followed by Reduction


51



Step 1. **5-Bromo-2-methoxypyridine:** A mixture of 2,5-dibromopyridine (5.5 g, 23.2 mmol) and NaOMe (3.76g, 69.6 mmol) in MeOH (60 mL) was heated at 70 °C in a sealed reaction vessel for 42 h, then allowed to cool to room temp. The reaction mixture was treated with water (50 mL) and extracted with EtOAc (2 x 100 mL). The combined organic layers were dried (Na₂SO₄) and concentrated under reduced pressure to give a pale yellow, volatile oil (4.1g, 95% yield): TLC (10% EtOAc / 90% hexane) R_f 0.57.




Step 2. **5-Hydroxy-2-methoxypyridine:** To a stirred solution of 5-bromo-2-methoxypyridine (8.9 g, 47.9 mmol) in THF (175 mL) at -78 °C was added an n-butyllithium solution (2.5 M in hexane; 28.7 mL, 71.8 mmol) dropwise and the resulting mixture was allowed to stir at -78 °C for 45 min. Trimethyl borate (7.06 mL, 62.2 mmol) was added via syringe and the resulting mixture was stirred for an additional 2 h. The bright orange reaction mixture was warmed to 0 °C and was treated with a mixture of a 3 N NaOH solution (25 mL, 71.77 mmol) and a hydrogen peroxide solution (30%; approx. 50 mL). The resulting yellow and slightly turbid reaction mixture was warmed to room temp. for 30 min and then heated to the reflux temp. for 1 h. The reaction mixture was then allowed to cool to room temp. The aqueous layer was neutralized with a 1N HCl solution then extracted with Et₂O (2 x 100 mL). The combined organic layers were dried (Na₂SO₄) and concentrated under reduced pressure to give a viscous yellow oil (3.5g, 60%).




Step 3. **4-(5-(2-Methoxy)pyridyl)oxy-1-nitrobenzene:** To a stirred slurry of NaH (97%, 1.0 g, 42 mmol) in anhyd DMF (100 mL) was added a solution of 5-hydroxy-2-methoxypyridine (3.5g, 28 mmol) in DMF (100 mL). The resulting mixture was allowed to stir at room temp. for 1 h, 4-fluoronitrobenzene (3 mL, 28 mmol) was added via syringe. The reaction mixture was heated to 95 °C overnight, then treated with water (25 mL) and extracted with EtOAc (2 x 75 mL). The organic layer was dried (MgSO₄)

and concentrated under reduced pressure. The residual brown oil was crystallized (EtOAc/hexane) to afford yellow crystals (5.23 g, 75%).



Step 4. 4-(5-(2-Methoxy)pyridyl)oxyaniline: 4-(5-(2-Methoxy)pyridyl)oxy-1-nitrobenzene was reduced to the aniline in a manner analogous to that described in Method B3d, Step2.

A14a. General Method for Substituted Aniline Synthesis via Nucleophilic Aromatic Substitution using a Halopyridine




10

3-(4-Pyridinylthio)aniline: To a solution of 3-aminothiophenol (3.8 mL, 34 mmoles) in anhyd DMF (90mL) was added 4-chloropyridine hydrochloride (5.4 g, 35.6 mmoles) followed by K_2CO_3 (16.7 g, 121 mmoles). The reaction mixture was stirred at room temp. for 1.5 h, then diluted with EtOAc (100 mL) and water (100mL). The aqueous layer was back-extracted with EtOAc (2 x 100 mL). The combined organic layers were washed with a saturated NaCl solution (100 mL), dried ($MgSO_4$), and concentrated under reduced pressure. The residue was filtered through a pad of silica (gradient from 50% EtOAc/50% hexane to 70% EtOAc/30% hexane) and the resulting material was triturated with a Et_2O /hexane solution to afford the desired product (4.6 g, 66%): TLC (100 % ethyl acetate) R_f 0.29; 1H -NMR ($DMSO-d_6$) δ 5.41 (s, 2H), 6.64-6.74 (m, 3H), 7.01 (d, $J=4.8$, 2H), 7.14 (t, $J=7.8$ Hz, 1H), 8.32 (d, $J=4.8$, 2H).

15

20

A14b. General Method for Substituted Aniline Synthesis via Nucleophilic Aromatic Substitution using a Halopyridine




25


4-(2-Methyl-4-pyridinyloxy)aniline: To a solution of 4-aminophenol (3.6 g, 32.8 mmol) and 4-chloropicoline (5.0 g, 39.3 mmol) in anhyd DMPU (50 mL) was added

potassium *tert*-butoxide (7.4 g, 65.6 mmol) in one portion. The reaction mixture was heated at 100 °C with stirring for 18 h, then was allowed to cool to room temp. The resulting mixture was poured into water (200 mL) and extracted with EtOAc (3 x 150 mL). The combined extracts were sequentially washed with water (3 x 100 mL) and a saturated NaCl solution (2 x 100 mL), dried (Na₂SO₄), and concentrated *in vacuo*. The resulting oil was purified by flash chromatography (50 % EtOAc/50% hexane) to afford the desired product as a yellow oil (0.7 g, 9%): CI-MS *m/z* 201 ((M+H)⁺).

A14c. General Method for Substituted Aniline Synthesis via Nucleophilic Aromatic Substitution using a Halopyridine




Step 1. Methyl(4-nitrophenyl)-4-pyridylamine: To a suspension of *N*-methyl-4-nitroaniline (2.0 g, 13.2 mmol) and K₂CO₃ (7.2 g, 52.2 mmol) in DMPU (30mL) was added 4-chloropyridine hydrochloride (2.36 g, 15.77 mmol). The reaction mixture was heated at 90 °C for 20 h, then cooled to room temperature. The resulting mixture was diluted with water (100 mL) and extracted with EtOAc (100 mL). The organic layer was washed with water (100 mL), dried (Na₂SO₄) and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, gradient from 80% EtOAc /20% hexanes to 100% EtOAc) to afford methyl(4-nitrophenyl)-4-pyridylamine (0.42 g)




Step 2. Methyl(4-aminophenyl)-4-pyridylamine: Methyl(4-nitrophenyl)-4-pyridylamine was reduced in a manner analogous to that described in Method B1.

A15. General Method of Substituted Aniline Synthesis via Phenol Alkylation Followed by Reduction of a Nitroarene

54




Step 1. 4-(4-Butoxyphenyl)thio-1-nitrobenzene: To a solution of 4-(4-nitrophenylthio)phenol (1.50 g, 6.07 mmol) in anh DMF (75 ml) at 0 °C was added NaH (60% in mineral oil, 0.267 g, 6.67 mmol). The brown suspension was stirred at 0 °C until gas evolution stopped (15 min), then a solution of iodobutane (1.12 g, .690 ml, 6.07 mmol) in anh DMF (20 mL) was added dropwise over 15 min at 0 °C. The reaction was stirred at room temp. for 18 h at which time TLC indicated the presence of unreacted phenol, and additional iodobutane (56 mg, 0.035 mL, 0.303 mmol, 0.05 equiv) and NaH (13 mg, 0.334 mmol) were added. The reaction was stirred an additional 6 h room temp., then was quenched by the addition of water (400 mL). The resulting mixture was extracted with Et₂O (2 x 500 mL). The combined organics were washed with water (2 x 400 mL), dried (MgSO₄), and concentrated under reduced pressure to give a clear yellow oil, which was purified by silica gel chromatography (gradient from 20% EtOAc/80% hexane to 50% EtOAc/50% hexane) to give the product as a yellow solid (1.24 g, 67%): TLC (20% EtOAc/80% hexane) R_f 0.75; ¹H-NMR (DMSO-d₆) δ 0.92 (t, J= 7.5 Hz, 3H), 1.42 (app hex, J=7.5 Hz, 2H), 1.70 (m, 2H), 4.01 (t, J= 6.6 Hz, 2H), 7.08 (d, J=8.7 Hz, 2H), 7.17 (d, J=9 Hz, 2H), 7.51 (d, J= 8.7 Hz, 2H), 8.09 (d, J= 9 Hz, 2H).




Step 2. 4-(4-Butoxyphenyl)thioaniline: 4-(4-Butoxyphenyl)thio-1-nitrobenzene was reduced to the aniline in a manner analogous to that used in the preparation of 3-(trifluoromethyl)-4-(4-pyridinylthio)aniline (Method B3b, Step 2): TLC (33% EtOAc/77% hexane) R_f 0.38.

A16. General Method for Synthesis of Substituted Anilines by the Acylation of Diaminoarenes




4-(4-*tert*-Butoxycarbamoylbenzyl)aniline: To a solution of 4,4'-methylenedianiline (3.00 g, 15.1 mmol) in anhyd THF (50 mL) at room temp was added a solution of di-*tert*-butyl dicarbonate (3.30 g, 15.1 mmol) in anhyd THF (10 mL). The reaction mixture was heated at the reflux temp. for 3 h, at which time TLC indicated the presence of unreacted methylenedianiline. Additional di-*tert*-butyl dicarbonate (0.664 g, 3.03 mmol, 0.02 equiv) was added and the reaction stirred at the reflux temp. for 16 h. The resulting mixture was diluted with Et₂O (200 mL), sequentially washed with a saturated NaHCO₃ solution (100 mL), water (100 mL) and a saturated NaCl solution (50 mL), dried (MgSO₄), and concentrated under reduced pressure. The resulting white solid was purified by silica gel chromatography (gradient from 33% EtOAc/67% hexane to 50% EtOAc/50% hexane) to afford the desired product as a white solid (2.09 g, 46%): TLC (50% EtOAc/50% hexane) R_f 0.45; ¹H-NMR (DMSO-d₆) δ 1.43 (s, 9H), 3.63 (s, 2H), 4.85 (br s, 2H), 6.44 (d, J=8.4 Hz, 2H), 6.80 (d, J=8.1 Hz, 2H), 7.00 (d, J=8.4 Hz, 2H), 7.28 (d, J=8.1 Hz, 2H), 9.18 (br s, 1H); FAB-MS m/z 298 (M⁺).

A17. General Method for the Synthesis of Aryl Amines via Electrophilic Nitration Followed by Reduction




Step 1. 3-(4-Nitrobenzyl)pyridine: A solution of 3-benzylpyridine (4.0 g, 23.6 mmol) and 70% nitric acid (30 mL) was heated overnight at 50 °C. The resulting mixture was allowed to cool to room temp. then poured into ice water (350 mL). The aqueous mixture then made basic with a 1N NaOH solution, then extracted with Et₂O (4 x 100 mL). The combined extracts were sequentially washed with water (3 x 100 mL) and a saturated NaCl solution (2 x 100 mL), dried (Na₂SO₄), and concentrated *in vacuo*. The residual oil was purified by MPLC (silica gel; 50 % EtOAc/50% hexane) then recrystallization (EtOAc/hexane) to afford the desired product (1.0 g, 22%): GC-MS m/z 214 (M⁺).




Step 2. 3-(4-Pyridinyl)methylaniline: 3-(4-Nitrobenzyl)pyridine was reduced to the aniline in a manner analogous to that described in Method B1.

5 A18. General Method for Synthesis of Aryl Amines via Substitution with Nitrobenzyl Halides Followed by Reduction




Step 1. 4-(1-Imidazolylmethyl)-1-nitrobenzene: To a solution of imidazole (0.5 g, 7.3 mmol) and 4-nitrobenzyl bromide (1.6 g, 7.3 mmol) in anhydrous acetonitrile (30 mL) was added K₂CO₃ (1.0 g, 7.3 mmol). The resulting mixture was stirred at room temp. for 18 h and then poured into water (200 mL) and the resulting aqueous solution was extracted with EtOAc (3 x 50 mL). The combined organic layers were sequentially washed with water (3 x 50 mL) and a saturated NaCl solution (2 x 50 mL), dried (MgSO₄), and concentrated *in vacuo*. The residual oil was purified by MPLC (silica gel; 25% EtOAc/75% hexane) to afford the desired product (1.0 g, 91%); EI-MS *m/z* 203 (M⁺).




Step 2. 4-(1-Imidazolylmethyl)aniline: 4-(1-Imidazolylmethyl)-1-nitrobenzene was reduced to the aniline in a manner analogous to that described in Method B2.

20 A19. Formation of Substituted Hydroxymethylanilines by Oxidation of Nitrobenzyl Compounds Followed by Reduction




Step 1. 4-(1-Hydroxy-1-(4-pyridyl)methyl)-1-nitrobenzene: To a stirred solution of 3-(4-nitrobenzyl)pyridine (6.0 g, 28 mmol) in CH₂Cl₂ (90 mL) was added *m*-CPBA (5.80 g, 33.6 mmol) at 10 °C, and the mixture was stirred at room temp. overnight. The reaction mixture was successively washed with a 10% NaHSO₃ solution (50 mL), a saturated K₂CO₃ solution (50 mL) and a saturated NaCl solution (50 mL), dried (MgSO₄) and

concentrated under reduced pressure. The resulting yellow solid (2.68 g) was dissolved in anhydrous acetic anhydride (30 mL) and heated at the reflux temperature overnight. The mixture was concentrated under reduced pressure. The residue was dissolved in MeOH (25 mL) and treated with a 20% aqueous NH_3 solution (30 mL). The mixture was stirred at room temp. for 1 h, then was concentrated under reduced pressure. The residue was poured into a mixture of water (50 mL) and CH_2Cl_2 (50 mL). The organic layer was dried (MgSO_4), concentrated under reduced pressure, and purified by column chromatography (80% EtOAc/ 20% hexane) to afford the desired product as a white solid. (0.53 g, 8%): mp 110-118 °C; TLC (80% EtOAc/20% hexane) R_f 0.12; FAB-MS m/z 367 ($(\text{M}+\text{H})^+$, 100%).



Step 2. 4-(1-Hydroxy-1-(4-pyridyl)methyl)aniline: 4-(1-Hydroxy-1-(4-pyridyl)methyl-1-nitrobenzene was reduced to the aniline in a manner analogous to that described in Method B3d, Step2.


A20. Formation of 2-(*N*-methylcarbamoyl)pyridines via the Menisci reaction



Step 1. 2-(*N*-methylcarbamoyl)-4-chloropyridine. (Caution: this is a highly hazardous, potentially explosive reaction.) To a solution of 4-chloropyridine (10.0 g) in *N*-methylformamide (250 mL) under argon at ambient temp was added conc. H_2SO_4 (3.55 mL) (exotherm). To this was added H_2O_2 (17 mL, 30% wt in H_2O) followed by $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$ (0.55 g) to produce an exotherm. The reaction was stirred in the dark at ambient temp for 1h then was heated slowly over 4 h at 45 °C. When bubbling subsided, the reaction was heated at 60 °C for 16 h. The opaque brown solution was diluted with H_2O (700 mL) followed by a 10% NaOH solution (250 mL). The aqueous mixture was extracted with EtOAc (3 x 500 mL) and the organic layers were washed separately with a saturated NaCl solution (3 x 150 mL). The combined organics were

dried (MgSO_4) and filtered through a pad of silica gel eluting with EtOAc. The solvent was removed in vacuo and the brown residue was purified by silica gel chromatography (gradient from 50% EtOAc / 50% hexane to 80% EtOAc / 20% hexane). The resulting yellow oil crystallized at 0 °C over 72 h to give 2-(*N*-methylcarbamoyl)-4-chloropyridine in yield (0.61 g, 5.3%): TLC (50% EtOAc/50% hexane) R_f 0.50; MS; ^1H NMR (CDCl_3): δ 8.44 (d, 1 H, $J = 5.1$ Hz, CHN), 8.21 (s, 1H, CHCCO), 7.96 (b s, 1H, NH), 7.43 (dd, 1H, $J = 2.4, 5.4$ Hz, ClCHCN), 3.04 (d, 3H, $J = 5.1$ Hz, methyl); CI-MS m/z 171 ((M+H)+).

10 A21. General method for the Synthesis of ω -Sulfonylphenyl Anilines




Step 1. 4-(4-Methylsulfonylphenoxy)-1-nitrobenzene: To a solution of 4-(4-methylthiophenoxy)-1-nitrobenzene (2 g, 7.66 mmol) in CH_2Cl_2 (75 mL) at 0 °C was slowly added *m*CPBA (57-86%, 4 g), and the reaction mixture was stirred at room temperature for 5 h. The reaction mixture was treated with a 1 N NaOH solution (25 mL). The organic layer was sequentially washed with a 1N NaOH solution (25 mL), water (25 mL) and a saturated NaCl solution (25 mL), dried (MgSO_4), and concentrated under reduced pressure to give 4-(4-methylsulfonylphenoxy)-1-nitrobenzene as a solid (2.1 g).


20

Step 2. 4-(4-Methylsulfonylphenoxy)-1-aniline: 4-(4-Methylsulfonylphenoxy)-1-nitrobenzene was reduced to the aniline in a manner analogous to that described in Method B3d, step 2.

25 A22. General Method for Synthesis of ω -Alkoxy- ω -carboxyphenyl Anilines



Step 1. 4-(3-Methoxycarbonyl-4-methoxyphenoxy)-1-nitrobenzene: To a solution of 4-(3-carboxy-4-hydroxyphenoxy)-1-nitrobenzene (prepared in a manner analogous to that described in Method B3a, step 1, 12 mmol) in acetone (50 mL) was added K_2CO_3 (5 g) and dimethyl sulfate (3.5 mL). The resulting mixture was heated at the reflux temperature overnight, then cooled to room temperature and filtered through a pad of Celite®. The resulting solution was concentrated under reduced pressure, absorbed onto silica gel, and purified by column chromatography (50% EtOAc / 50% hexane) to give 4-(3-methoxycarbonyl-4-methoxyphenoxy)-1-nitrobenzene as a yellow powder (3 g): mp 115-118 °C.




10

Step 2. 4-(3-Carboxy-4-methoxyphenoxy)-1-nitrobenzene: A mixture of 4-(3-methoxycarbonyl-4-methoxyphenoxy)-1-nitrobenzene (1.2 g), KOH (0.33 g), and water (5 mL) in MeOH (45 mL) was stirred at room temperature overnight and then heated at the reflux temperature for 4 h. The resulting mixture was cooled to room temperature and concentrated under reduced pressure. The residue was dissolved in water (50 mL), and the aqueous mixture was made acidic with a 1N HCl solution. The resulting mixture was extracted with EtOAc (50 mL). The organic layer was dried ($MgSO_4$) and concentrated under reduced pressure to give 4-(3-carboxy-4-methoxyphenoxy)-1-nitrobenzene (1.04 g).

20

B. General Methods of Urea Formation


B1a. General Method for the Reaction of an Aryl Amine with an Aryl Isocyanate



N-(5-*tert*-Butyl-2-(3-tetrahydrofuranyloxy)phenyl)-*N'*-(4-methylphenyl)urea: To a solution of 5-*tert*-butyl-2-(3-tetrahydrofuranyloxy)aniline (0.078 g, 0.33 mmol) in toluene (2.0 mL) was added *p*-tolyl isocyanate (0.048 g, 0.36 mmol) and the resulting mixture was allowed to stir at room temp. for 8 h to produce a precipitate. The reaction mixture was filtered and the residue was sequentially washed with toluene and hexanes to give the desired urea as a white solid (0.091 g, 75%): mp 229-231 °C; ¹H-NMR (DMSO-*d*₆) δ 1.30 (s, 9H), 1.99-2.03 (m, 1H), 2.19-2.23 (m, 4H), 3.69-3.76 (m, 1H), 3.86-3.93 (m, 3H), 4.98-5.01 (m, 1H), 6.81-6.90 (m, 2H), 7.06 (d, *J*=8.09 Hz, 2H), 7.32 (d, *J*=8.09 Hz, 2H), 7.84 (s, 1H), 8.22 (d, *J*=2.21 Hz, 1H), 9.26 (s, 1H).

10

B1b. General Method for the Reaction of an Aryl Amine with an Aryl Isocyanate




N-(2-Methoxy-5-(trifluoromethanesulfonyl)phenyl)-*N'*-(4-methylphenyl)urea: *p*-Tolyl isocyanate (0.19 mL, 1.55 mmol) was added to a solution of 2-methoxy-5-(trifluoromethanesulfonyl)aniline (0.330 g, 1.29 mmol) in EtOAc (5 mL), and the reaction mixture was stirred at room temp. for 18 h. The resulting precipitate was collected by filtration and washed with Et₂O to give a white solid (0.28 g). This material was then purified by HPLC (C-18 column, 50% CH₃CN/50% H₂O) and the resulting solids were triturated with Et₂O to provide the title compound (0.198 g): ¹H-NMR (CDCl₃) δ 7.08 (d, *J*=8.5 Hz, 2H), 7.33 (d, *J*=8.5 Hz, 2H), 7.40 (d, *J*=8.8 Hz, 1H), 7.71 (dd, *J*=2.6, 8.8 Hz, 1H), 8.66 (s, 1H), 8.90 (d, *J*=2.6 Hz, 1H), 9.36 (s, 1H); FAB-MS *m/z* 389 ((*M*+1)⁺).

20


B1c. General Method for the Reaction of an Aryl Amine with an Aryl Isocyanate

61




***N*-(2-Methoxy-5-(difluoromethanesulfonyl)phenyl)-*N'*-(4-methylphenyl)urea:** *p*-Tolyl isocyanate (0.058 mL, 0.46 mmol) was added to a solution of 2-methoxy-5-(difluoromethanesulfonyl)aniline (0.100 g, 0.42 mmol) in EtOAc (0.5 mL) and the resulting mixture was stirred at room temp. for 3 d. The resulting precipitate was filtered and washed with Et₂O to provide the title compound as a white solid (0.092 g): ¹H-NMR (CDCl₃) δ 2.22 (s, 3H) 4.01 (s, 3H), 7.02-7.36 (m, 6H), 7.54 (dd, *J*=2.4, 8.6 Hz, 1H), 8.57 (s, 1H), 8.79 (d, *J*=2.6 Hz, 1H), 9.33 (s, 1H); EI-MS *m/z* 370 (*M*⁺).

10 **B1d. General Method for the Reaction of an Aryl Amine with an Aryl Isocyanate**




***N*-(2,4-Dimethoxy-5-(trifluoromethyl)phenyl)-*N'*-(4-methylphenyl)urea:** *p*-Tolyl isocyanate (0.16 mL, 1.24 mmol) was added to a solution of 2,4-dimethoxy-5-(trifluoromethyl)aniline (0.25 g, 1.13 mmol) in EtOAc (3 mL) and the resulting mixture was stirred at room temp. for 18 h. A resulting precipitate was washed with Et₂O to give the title compound as a white solid (0.36 g): ¹H-NMR (CDCl₃) δ 2.21 (s, 3H), 3.97 (s, 3H), 3.86 (s, 3H), 6.88 (s, 1H), 7.05 (d, *J*=8.5 Hz, 2H), 7.29 (d, *J*=8.5 Hz, 2H), 8.13 (s, 1H), 8.33 (s, 1H), 9.09 (s, 1H); FAB-MS *m/z* 355 (*(M+1)*⁺).

20 **B1e. General Method for the Reaction of an Aryl Amine with an Aryl Isocyanate**




N-(3-Methoxy-2-naphthyl)-*N'*-(1-naphthyl)urea: To a solution of 2-amino-3-methoxynaphthalene (0.253 g, 1.50 mmol) in CH₂Cl₂ (3 mL) at room temp. was added a solution of 1-naphthyl isocyanate (0.247 g, 1.50 mmol) in CH₂Cl₂ (2 mL) and the resulting mixture was allowed to stir overnight. The resulting precipitate was separated and washed with CH₂Cl₂ to give the desired urea as a white powder (0.450 g, 90%): mp 235-236 °C; ¹H-NMR (DMSO-d₆) δ 4.04 (s, 3H), 7.28-7.32 (m, 2H), 7.38 (s, 1H), 7.44-7.72 (m, 6H), 7.90-7.93 (m, 1H), 8.05-8.08 (m, 1H), 8.21-8.24 (m, 1H), 8.64 (s, 1H), 9.03 (s, 1H), 9.44 (s, 1H); FAB-MS *m/z* 343 ((M+H)⁺).

10 **B1f. General Method for the Reaction of an Aryl Amine with an Aryl Isocyanate**




N-(5-*tert*-Butyl-2-(2-*tert*-butoxycarbonyloxy)ethoxy)phenyl)-*N'*-(4-methylphenyl)urea: A mixture of 5-*tert*-butyl-2-(2-*tert*-butoxycarbonyloxy)ethoxyaniline (Method A10, 0.232 g, 0.75 mmol) and *p*-tolyl isocyanate (0.099 mL, 0.79 mmol) in EtOAc (1 mL) was stirred at room temp. for 3 d to produce a solid, which was separated. The filtrate was purified by column chromatography (100% CH₂Cl₂) and the residue was triturated (Et₂O/hexane) to give the desired product (0.262 g, 79%): mp 155-156 °C; TLC (20% EtOAc/80% hexane) *R_f* 0.49; ¹H-NMR (DMSO-d₆) δ 1.22 (s, 9H), 1.37 (s, 9H), 2.21 (s, 3H), 4.22-4.23 (m, 2H), 4.33-4.35 (m, 2H), 6.89-7.00 (m, 4H), 7.06 (d, *J*=8.5 Hz, 2H), 7.32 (d, *J*=8.1 Hz, 2H), 7.96 (s, 1H); 8.22 (d, *J*=1.5 Hz, 1H), 9.22 (s, 1H); FAB-MS *m/z* (rel abundance) 443 ((M+H)⁺, 6%).

25 **B2a. General Method for Reaction of an Aryl Amine with Phosgene Followed by Addition of a Second Aryl Amine**



***N*-(2-Methoxy-5-(trifluoromethyl)phenyl)-*N'*-(3-(4-pyridinylthio)phenyl)urea:** To a solution of pyridine (0.61 mL, 7.5 mmol, 3.0 equiv) and phosgene (20% in toluene; 2.65 mL, 5.0 mmol, 2.0 equiv) in CH_2Cl_2 (20 mL) was added 2-methoxy-5-(trifluoromethyl)aniline (0.48 g, 2.5 mmol) at 0 °C. The resulting mixture was allowed warm to room temp. stirred for 3 h, then treated with anh. toluene (100 mL) and concentrated under reduced pressure. The residue was suspended in a mixture of CH_2Cl_2 (10 mL) and anh. pyridine (10 mL) and treated with 3-(4-pyridinylthio)aniline (0.61 g, 2.5 mmol, 1.0 equiv). The mixture was stirred overnight at room temp., then poured into water (50 mL) and extracted with CH_2Cl_2 (3 x 25 mL). The combined organic layers were dried (MgSO_4) and concentrated under reduced pressure. The residue was dissolved in a minimal amount of CH_2Cl_2 and treated with pet. ether to give the desired product as a white precipitate (0.74 g, 70%): mp 202 °C; TLC (5% acetone/95% CH_2Cl_2) R_f 0.09; ^1H -NMR ($\text{DMSO}-d_6$) δ 7.06 (d, $J=5.5$ Hz, 2H), 7.18 (dd, $J=2.4, 4.6$ Hz, 2H), 7.31 (dd, $J=2.2, 9.2$ Hz, 1H), 7.44 (d, $J=5.7$ Hz, 1H), 7.45 (s, 1H), 7.79 (d, $J=2.2$ Hz, 1H), 8.37 (s, 2H), 8.50 (dd, $J=2.2, 9.2$ Hz, 2H), 9.63 (s, 1H), 9.84 (s, 1H); FAB-MS m/z 420 ($(\text{M}+\text{H})^+$, 70%).


B2b. General Method for Reaction of an Aryl Amine with Phosgene Followed by Addition of a Second Aryl Amine



***N*-(2-Methoxy-5-(trifluoromethyl)phenyl)-*N'*-(4-(4-pyridinylthio)phenyl)urea:** To a solution of pyridine (0.61 mL, 7.5 mmol, 3.0 equiv) and phosgene (20% in toluene; 2.65 mL, 5.0 mmol, 2.0 equiv) in CH_2Cl_2 (20 mL) was added 4-(4-pyridinylthio)aniline (0.506

g, 2.5 mmol) at 0 °C. After stirring for 3 h at room temp., the mixture was treated with anhyd. toluene (100 mL) then concentrated under reduced pressure. The residue was suspended in a mixture of CH₂Cl₂ (10 mL) and anhyd. pyridine (10 mL) and treated with 2-methoxy-5-(trifluoromethyl)aniline (0.50 g, 2.5 mmol, 1.0 equiv). After stirring the mixture overnight at room temp., it was poured into a 1 N NaOH solution (50 mL) and extracted with CH₂Cl₂ (3 x 25 mL). The combined organic layers were dried (MgSO₄) and concentrated under reduced pressure to give the desired urea (0.74 g, 71%): mp 215 °C; TLC (5% acetone/95% CH₂Cl₂) R_f 0.08; ¹H-NMR (DMSO-d₆) δ 3.96 (s, 3H), 6.94 (dd, J=1.1, 4.8 Hz, 2H), 7.19 (d, J=8.4 Hz, 1H), 7.32 (dd, J=2.2, 9.3 Hz, 1H), 7.50 (d, J=8.8 Hz, 2H), 7.62 (d, J=8.8 Hz, 2H), 8.32 (d, J=5.1 Hz, 2H), 8.53 (d, J=0.7 Hz, 1H), 8.58 (s, 1H), 9.70 (s, 1H); FAB-MS m/z 420 ((M+H)⁺).


B3a. General Method for the Reaction of an Aryl Amine with Phosgene with Isolation of the Isocyanate, Followed by Reaction with a Second Aryl Amine



15


Step 1. 5-(Difluoromethanesulfonyl)-2-methoxyphenyl isocyanate: To a solution of phosgene (1.95 M in toluene; 3.0 mL, 5.9 mmol) in CH₂Cl₂ (40 mL) at 0 °C was added a solution of 5-(difluoromethanesulfonyl)-2-methoxyaniline (0.70 g, 2.95 mmol) and pyridine (0.44 mL, 8.85 mmol) in CH₂Cl₂ (10 mL) dropwise. After being stirred at 0 °C for 30 min and at room temp. for 3 h, the reaction mixture was concentrated under reduced pressure, then treated with toluene (50 mL). The resulting mixture was concentrated under reduced pressure, then was treated with Et₂O (50 mL) to produce a precipitate (pyridinium hydrochloride). The resulting filtrate was concentrated under reduced pressure to provide the title compound as a white solid (0.33 g). This material was used in the next step without further purification.

25




Step 2. *N*-(2-Methoxy-5-(difluoromethanesulfonyl)phenyl)-*N'*-(2-fluoro-4-methylphenyl)urea: 2-Fluoro-4-methylaniline (0.022 mL, 0.19 mmol) was added to a solution of 5-(difluoromethanesulfonyl)-2-methoxyphenyl isocyanate (0.046 g, 0.17 mmol) in EtOAc (1 mL). The reaction mixture was stirred at room temp. for 3 d. The resulting precipitate was washed with Et₂O to provide the title compound as a white solid (0.055 g): ¹H-NMR (CDCl₃) δ 2.24 (s, 3H), 4.01 (s, 3H), 6.93 (d, *J*=8.5 Hz, 1H), 7.01-7.36 (m, 3H), 7.56 (dd, *J*=2.4, 8.6 Hz, 1H), 7.98 (app t, *J*=8.6 Hz, 1H), 8.79 (d, *J*=2.2 Hz, 1H), 9.07 (s, 1H), 9.26 (s, 1H); FAB-MS *m/z* 389 ((*M*+1)⁺).

B3b. General Method for the Reaction of an Aryl Amine with Phosgene with Isolation of the Isocyanate, Followed by Reaction with a Second Aryl Amine




Step 1. 2-Methoxy-5-trifluoromethylphenyl Isocyanate: To a solution of phosgene (1.93 M in toluene; 16 mL, 31.4 mmol) in CH₂Cl₂ (120 mL) at 0 °C was added a solution of 2-methoxy-5-(trifluoromethyl)aniline (3.0 g, 15.7 mmol) and pyridine (2.3 mL, 47.1 mmol) in CH₂Cl₂ (30 mL) dropwise. The resulting mixture was stirred at 0 °C for 30 min and at room temp for 3 h, then concentrated under reduced pressure. The residue was diluted with toluene (30 mL), concentrated under reduced pressure, and treated with Et₂O. The resulting precipitate (pyridinium hydrochloride) was removed and the filtrate was concentrated under reduced pressure to give the title compound as a yellow oil (3.0 g) which crystallized upon standing at room temp. for a few days.




Step 2. *N*-(2-Methoxy-5-(trifluoromethyl)phenyl)- *N'*-(4-fluorophenyl)urea: 4-Fluoroaniline (0.24 mL, 2.53 mmol) was added to a solution of 2-methoxy-5-(trifluoromethyl)phenyl isocyanate (0.50 g, 2.30 mmol) in EtOAc (6 mL) and the reaction mixture was stirred at room temp. for 3 d. The resulting precipitate was washed with Et₂O to give the title compound as a white solid (0.60 g): NMR: 3.94 (s, 3H), 7.13-7.18 (m, 3H), 7.30 (dd, *J*=1.5, 8.4 Hz, 1H), 7.44 (m, 2H), 8.45 (s, 1H), 8.52 (d, *J*=2.2 Hz, 1H), 9.42 (s, 1H); FAB-MS *m/z* 329 ((*M*+1)⁺).

10 **B4. General Method for Urea Formation via Curtius Rearrangement, Followed by Trapping with an Amine**




15 *N*-(3-Methoxy-2-naphthyl)-*N'*-(4-methylphenyl)urea: To a solution of 3-methoxy-2-naphthoic acid (Method A6, Step 2; 0.762 g, 3.80 mmol) and Et₃N (0.588 mL, 4.2 mmol) in anhydrous toluene (20 mL) at room temp. was added a solution of diphenylphosphoryl azide (1.16 g, 4.2 mmol) in toluene (5 mL). The resulting mixture was heated to 80 °C for 2 h, cooled to room temp., and *p*-toluidine (0.455 g, 4.1 mmol) was added. The mixture was heated at 80 °C overnight, cooled to room temp., quenched with a 10% citric acid solution, and extracted with EtOAc (2 x 25 mL). The combined organic layers were washed with a saturated NaCl solution (25 mL), dried (MgSO₄), and concentrated *in vacuo*. The residue was triturated with CH₂Cl₂ to give the desired urea as white powder (0.700 g, 61%): mp 171-172 °C; ¹H-NMR (DMSO-*d*₆) δ 2.22 (s, 3H), 3.99 (s, 3H), 7.07 (d, *J*=8.49 Hz, 2H), 7.27-7.36 (m, 5H), 7.67-7.72 (m, 2H), 8.43 (s, 1H), 8.57 (s, 1H), 9.33 (s, 1H); FAB-MS *m/z* 307 ((*M*+H)⁺).

25 **B5. General Method for the Reaction of Substituted Aniline with *N,N'*-Carbonyldiimidazole Followed by Reaction with a Second Amine**



***N*-(5-Chloro-2-hydroxy-4-nitrophenyl)-*N'*-(4-(4-pyridinylmethyl)phenyl)urea:** A solution of 4-(4-pyridinylmethyl)aniline (0.300 g, 1.63 mmol) and *N,N'*-carbonyldiimidazole (0.268 g, 1.65 mmol) in CH_2Cl_2 (10 mL) was stirred at room temp. for 1 h at which time TLC analysis indicated no starting aniline. The reaction mixture was then treated with 2-amino-4-chloro-5-nitrophenol (0.318 g, 1.65 mmol) and stirred at 40-45 °C for 48 h. The resulting mixture was cooled to room temp. and diluted with EtOAc (25 mL). The resulting precipitate was separated to give the desired product (0.416 g, 64%): TLC (50% acetone/50% CH_2Cl_2) R_f 0.40; $^1\text{H-NMR}$ (DMSO-d_6) δ 3.90 (s, 2H), 7.18 (d, $J=8.4$ Hz, 2H), 7.21 (d, $J=6$ Hz, 2H), 7.38 (d, $J=8.4$ Hz, 2H), 7.54 (s, 1H), 8.43-8.45 (m, 3H), 8.78 (s, 1H), 9.56 (s, 1H), 11.8 (br s, 1H); FAB-MS m/z (rel abundance) 399 ($(\text{M}+\text{H})^+$, 10%).

B6. General Method for the Synthesis of Symmetrical Diphenyl Ureas as Side-Products of Urea Forming reactions




Bis(4-chloro-3-(trifluoromethyl)phenyl)urea: To a solution of 5-amino-3-*tert*-butylisoxazole (0.100 g) in anhydrous toluene (5 mL) was added 4-chloro-3-(trifluoromethyl)phenyl isocyanate (0.395 g). The reaction vessel was sealed, heated at 85 °C for 24 h, and cooled to room temp. The reaction mixture was added to a slurry of Dowex® 50WX2-100 resin (0.5 g) in CH_2Cl_2 (40 mL), and the resulting mixture was stirred vigorously for 72 h. The mixture was filtered and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (gradient from 100% CH_2Cl_2 to 5% MeOH/95% CH_2Cl_2) to give bis(4-chloro-3-(trifluoromethyl)phenyl)urea followed by *N*-(3-*tert*-butyl-5-isoxazolyl)-*N'*-(4-chloro-3-(trifluoromethyl)phenyl)urea. The residue from the symmetrical urea fractions was


trituated (Et₂O/hexane) to give the urea as a white solid (0.110 g): TLC (3% MeOH/97% CH₂Cl₂) R_f 0.55; FAB-MS *m/z* 417 ((M+H)⁺).

C. Urea Interconversions and Misc. Reactions


5 C1. General Method for Alkylation of Hydroxyphenyl Ureas




- Step 1. *N*-(2-Hydroxy-5-(trifluoromethylthio)phenyl)-*N'*-(4-methylphenyl)urea: *p*-Tolyl isocyanate (0.066 mL, 0.52 mmol) was added to a solution of 2-hydroxy-5-(trifluoromethylthio)aniline (0.100 g, 0.48 mmol) in EtOAc (2 mL) and the reaction mixture was stirred at room temp. for 2 d. The resulting precipitate was washed with EtOAc to provide the title compound (0.13 g): ¹H-NMR (CDCl₃) δ 2.24 (s, 3H), 7.44-7.03 (m, 6H), 8.46 (s, 1H), 8.60 (d, *J*=1.8 Hz, 1H), 9.16 (s, 1H), 10.41 (s, 1H); FAB-MS *m/z* 343 ((M+1)⁺). This material was used in the next step without purification.




- 15 Step 2. *N*-(2-Methoxy-5-(trifluoromethylthio)phenyl)-*N'*-(4-methylphenyl)urea: A solution of *N*-(2-hydroxy-5-(trifluoromethylthio)phenyl)-*N'*-(4-methylphenyl)urea (0.125 g, 0.36 mmol), iodomethane (0.045 mL, 0.73 mmol), and K₂CO₃ (100 mg, 0.73 mmol) in acetone (2 mL) was heated at the reflux temp. for 6 h, then was cooled to room temp. and concentrated under reduced pressure. The residue was dissolved in a minimal amount of MeOH, absorbed onto silica gel, and then purified by flash chromatography (3% Et₂O/97% CH₂Cl₂) to provide the title compound as a white solid (68 mg): ¹H-NMR (CDCl₃) δ 2.22 (s, 3H), 3.92 (s, 3H), 7.05-7.32 (m, 6H), 8.37 (s, 1H), 8.52 (d, *J*=2.2 Hz, 1H), 9.27 (s, 1H); FAB-MS *m/z* 357 ((M+1)⁺).

C2. General Method for the Reduction of Nitro-Containing Ureas

N-(5-*tert*-Butyl-2-methoxyphenyl)-*N'*-(2-amino-4-methylphenyl)urea: A solution of *N*-(5-*tert*-butyl-2-methoxyphenyl)-*N'*-(2-nitro-4-methylphenyl)urea (prepared in a manner analogous to Method B1a; 4.0 g, 11.2 mmol) in EtOH (100 mL) was added to a slurry of 10% Pd/C (0.40 g) in EtOH (10 mL), and the resulting mixture was stirred under an atmosphere of H₂ (balloon) at room temp. for 18 h. The mixture was filtered through a pad of Celite® and concentrated *in vacuo* to afford the desired product (3.42 g, 94%) as a powder: mp 165-166 °C; ¹H-NMR (DMSO-*d*₆) δ 1.30 (s, 9H), 2.26 (s, 3H), 3.50 (br s, 2H), 3.71 (s, 3H), 6.39 (br s, 1H), 6.62 (s, 1H), 6.73 (d, *J*=8.46 Hz, 1H), 6.99 (dd, *J*=2.21, 8.46 Hz, 1H), 7.05 (d, *J*=8.46 Hz, 1H), 7.29 (s, 1H), 8.22 (d, *J*=2.57 Hz, 1H); FAB-MS *m/z* 328 ((*M*+H)⁺).

C3. General Method of Thiourea Formation by Reaction with a Thioisocyanate

N-(5-*tert*-Butyl-2-methoxyphenyl)-*N'*-(1-naphthyl)thiourea: To a solution of 5-*tert*-butyl-2-methoxyaniline (0.372 g, 2.07 mmol) in toluene (5 mL) was added 1-naphthyl thioisocyanate (0.384 g, 2.07 mmol) and the resulting mixture was allowed to stir at room temp. for 8 h to produce a precipitate. The solids were separated and sequentially washed with toluene and hexane to give the desired product as an off-white powder (0.364 g, 48%): mp 158-160 °C; ¹H-NMR (DMSO-*d*₆) δ 1.31 (s, 9H), 3.59 (s, 3H), 6.74 (d, *J*=8.46 Hz, 1H), 7.13 (dd, *J*=2.21, 8.46 Hz, 1H), 7.53-7.62 (m, 4H), 7.88-7.95 (m, 4H), 8.06-8.08 (m, 1H), 8.09 (br s, 1H); FAB-MS *m/z* 365 ((*M*+H)⁺).


C4. General Method for Deprotection of *tert*-Butyl Carbonate-Containing Ureas

- N*-(5-*tert*-Butyl-2-(2-hydroxyethoxy)phenyl)-*N'*-(4-methylphenyl)urea: A solution of *N*-(5-*tert*-butyl-2-(2-*tert*-butoxycarbonyloxy)ethoxy)phenyl)-*N'*-(4-methylphenyl)urea
- 5 (Method B1f; 0.237 g, 0.54 mmol) and TFA (0.21 mL, 2.7 mmol) in CH₂Cl₂ (2 mL) was stirred at room temp for 18 h, then was washed with a saturated NaHCO₃ solution (2 mL). The organic layer was dried by passing through 1PS filter paper (Whatman®) and concentrated under reduced pressure. The resulting white foam was triturated (Et₂O/hexane), then recrystallized (Et₂O) to give the desired product (3.7 mg): TLC (50%
- 10 EtOAc/50% hexane) R_f 0.62; ¹H-NMR (DMSO-*d*₆) δ 1.22 (s, 9H), 3.75-3.76 (m, 2H), 4.00-4.03 (m, 2H), 4.80 (t, *J*=5.0 Hz, 1H), 6.88-6.89 (m, 4H), 7.06 (d, *J*=8.5 Hz, 2H), 7.33 (d, *J*=8.1 Hz, 2H), 7.97 (s, 1H), 8.20 br s, 1H), 9.14 (s, 1H); FAB-MS *m/z* (rel abundance) 343 ((*M*+*H*)⁺, 100%).


15
















The following compounds have been synthesized according to the General Methods listed above:

















Table 1. 2-Substituted-5-*tert*-butylphenyl Ureas





















































20

Example	R ¹	R ²	mp (°C)	TLC R _f	Solvent System	Mass Spec.	Source	Synth. Method
1	OH			0.54	2% MeOH / 98%	299 (M+H) ⁺	FAB	B1d

					CH ₂ Cl ₂			
2	OMe		199-200			313 (M+H) ⁺	FAB	B1d
3	OMe		208-209			390 (M) ⁺	EI	B1d
4	OMe		192-194			389 (M+H) ⁺	FAB	B1d
5	OMe			0.58	50% EtOAc / 50% hexane	347 (M+H) ⁺	FAB	B3b
6	OMe			0.62	50% EtOAc / 50% hexane	351 (M+H) ⁺	FAB	B3b
7	OMe			0.71	50% EtOAc / 50% hexane	331 (M+H) ⁺	FAB	B1d
8	OMe			0.74	50% EtOAc / 50% hexane	331 (M+H) ⁺	FAB	B3b
9	OMe			0.66	20% EtOAc / 80% hexane	327 (M+H) ⁺	FAB	B1d
10	OMe			0.62	20% EtOAc / 80% hexane	331 (M+H) ⁺	FAB	B1d
11	OMe			0.42	13% EtOAc / 87% hexane	335 (M+H) ⁺	FAB	B1d
12	OMe			0.52	2% MeOH / 98% CH ₂ Cl ₂	327 (M+H) ⁺	FAB	B1d
13	OMe			0.56	2% MeOH / 98% CH ₂ Cl ₂	335 (M+H) ⁺	FAB	B1d
14	OMe			0.48	2% MeOH / 98% CH ₂ Cl ₂	351 (M+H) ⁺	FAB	B1d
15	OMe			0.50	2% MeOH / 98% CH ₂ Cl ₂	347 (M+H) ⁺	FAB	B1d
16	OMe		201-202			390 (M+H) ⁺	FAB	B2a





17	OMe		199-200			390 (M+H)+	FAB	B2a
18	OMe		198-199	0.45	25% EtOAc / 75% hexane			B1a
19	OMe		181-182			389 (M+H)+	CI	B2a
20	OMe		181-183			390 (M+)	EI	B1a
21	OMe		175-177			358 (M+H)+	FAB	B1a
22	OMe		219-220			358 (M+H)+	FAB	B1a
23	OMe		165-166			328 (M+H)+	FAB	C2
24	OMe		102-104			271 (M+H)+	FAB	C2
25	OMe		236-238			349 (M+H)+	FAB	B1a
26	OMe		192-194			367 (M+H)+	FAB	B1a
27	OMe		137-140			550 (M+H)+	FAB	B2a
28	OMe		197-199			434 (M+H)+	CI	A8, B2a
29	OMe		212-215			416 (M+H)+	FAB	B2a
30	OMe		195			405 (M+H)+	FAB	B1c
31	OMe		110	0.07	5% acetone / 95% CH2Cl2	408 (M+H)+	FAB	B2b
32	OMe		185	0.67	5% acetone / 95% CH2Cl2	425 (M+H)+	FAB	B2a

33	OMe		214-215	0.54	5% acetone / 95% CH ₂ Cl ₂	448 (M+H) ⁺	FAB	B2a
34	OMe		180	0.56	5% acetone / 95% CH ₂ Cl ₂	421 (M+H) ⁺	FAB	B2a
35				0.67	50% EtOAc / 50% hexane	343 (M+H) ⁺	FAB	A10, B1f, C4
36				0.45	50% EtOAc / 50% hexane	340 (M+H) ⁺	FAB	B1d
37			222-223			354 (M+H) ⁺	ES	B1c
38			203-205			366 (M+H) ⁺	FAB	B1d
39			230-232			367 (M+H) ⁺	FAB	B1d
40			197-198			406 (M+H) ⁺	FAB	A9, B1a
41			204-205			392 (M+H) ⁺	FAB	A9, B1a
42			217-218			424 (M+H) ⁺	FAB	A9, B1a
43			187-188			370 (M+H) ⁺	FAB	A9, B1a
44			118-120			462 (M+H) ⁺	FAB	A9, B1a
45			146-148			448 (M+H) ⁺	FAB	A9, B1a

46			110-113			480 (M+H)+	FAB	A9, B1a
47			95-100			400 (M+H)+	FAB	A9, B1a
48			107-110			398 (M+H)+	FAB	A9, B1a
49			180-182			472 (M+H)+	FAB	A9, B1a
50			217-219			388 (M+H)+	FAB	A9, B1a
51			116-120			420 (M+H)+	FAB	A9, B1a
52			100-105			406 (M+H)+	FAB	A9, B1a
53			103-105			438 (M+H)+	FAB	A9, B1a
54			118-120			384 (M+H)+	FAB	A9, B1a
55			125-128			394 (M+H)+	FAB	A1, B1a
56			227-230			468 (M+H)+	FAB	A1, B1a
57			154-156			434 (M+H)+	FAB	A1, B1a
58			169-171			373 (M+H)+	FAB	A2, B1a

59			157-159			423 (M+H)+	FAB	A2, B1a
60			229-231			369 (M+H)+	FAB	A2, B1a
61			200-204			468 (M+H)+	FAB	B2a
62			187-188			508 (M+H)+	FAB	B2a
63			204-206			413 (M+H)+	FAB	B1a
64			192-194			389 (M+H)+	FAB	A7, B1a
65			183-185			425 (M+H)+	FAB	A7, B1a
66			159-160			443 (M+H)+	FAB	A7, B1a
67			179-180			411 (M+H)+	FAB	A7, B1a
68				0.06	10% EtOAc / 90% hexane	408 (M+H)+	FAB	A7, B1a
69			227-229			377 (M+H)+	FAB	A7, B1a
70			216-217			381 (M+H)+	FAB	A7, B1a
71			213-214			431 (M+H)+	FAB	A7, B1a
72			200-201			399 (M+H)+	FAB	A7, B1a
73			134-136			443 (M+)	EI	A7, B1a


76

74			185-186			459 (M+H)+	FAB	A7, B1a
75			207-208			419 (M+H)+	FAB	A7, B1a












77










Table 2.

2-Substituted-5-(trifluoromethyl)phenyl Ureas



Example	R ¹	R ²	mp (°C)	TL C R _f	Solvent System	Mass Spec.	Source	Synth. Method
76	OMe		185- 186			325 (M+H) ⁺	FAB	B1d
77	OMe			0.2 2	20% EtOAc / 80% hexane	329 (M+H) ⁺	FAB	B3b
78	OMe			0.4 9	20% EtOAc / 80% hexane	343 (M+H) ⁺	FAB	B3b
79	OMe			0.3 2	20% EtOAc / 80% hexane	343 (M+H) ⁺	FAB	B3b
80	OMe			0.3 7	20% EtOAc / 80% hexane	359 (M+H) ⁺	FAB	B3b
81	OMe			0.4 4	20% EtOAc / 80% hexane	363 (M+H) ⁺	FAB	B3b
82	OMe			0.6 8	50% EtOAc / 50%	339 (M+H) ⁺	FAB	B1d

					hexane			
83	OMe			0.6 8	50% EtOAc / 50% hexane	343 (M+H)+	FAB	B1d
84	OMe			0.6 0	50% EtOAc / 50% hexane	347 (M+H)+	FAB	B1d
85	OMe			0.5 3	2% MeOH / 98% CH2Cl2	339 (M+H)+	FAB	B1d
86	OMe			0.2 9	2% MeOH / 98% CH2Cl2	347 (M+H)+	FAB	B1d
87	OMe			0.2 7	2% MeOH / 98% CH2Cl2	363 (M+H)+	FAB	B1d
88	OMe			0.4 5	2% MeOH / 98% CH2Cl2	359 (M+H)+	FAB	B1d
89	OMe		184- 185			401 (M+H)+	FAB	B2a
90	OMe		176- 178			402 (M+)	EI	B1a
91	OMe		231- 233			361 (M+H)+	FAB	B1a
92	OMe		192- 194			379 (M+H)+	FAB	B1a
93	OMe		198			417 (M+H)+	FAB	B1e

94	OMe		206	0.5 8	5% acetone / 95% CH ₂ Cl ₂	437 (M+H) ⁺	FAB	B2a
95	OMe		98-99	0.5 0	5% acetone / 95% CH ₂ Cl ₂			B2a
96	OMe		190	0.6 5	5% acetone / 95% CH ₂ Cl ₂			B2a
97	OMe		194	0.7 6	5% acetone / 95% CH ₂ Cl ₂	464 (M+H) ⁺	FAB	B2a
98	OMe		210- 211	0.0 7	5% acetone / 95% CH ₂ Cl ₂	402 (M+H) ⁺	FAB	B2a
99	OMe		202	0.0 9	5% acetone / 95% CH ₂ Cl ₂	420 (M+H) ⁺	FAB	B2a
100	OMe		215	0.0 8	5% acetone / 95% CH ₂ Cl ₂	420 (M+H) ⁺	FAB	B2a
101	OMe		206	0.0 5	5% acetone / 95% CH ₂ Cl ₂	404 (M+H) ⁺	FAB	B2a
102	OMe			0.7 8	5% acetone / 95% CH ₂ Cl ₂	471 (M+H) ⁺	FAB	B1a














103	OMe					471 (M+H)+	FAB	B1a
104	OMe					487 (M+H)+	FAB	B1a
105				0.6 5	20% EtOAc / 80% hexane	352 (M+H)+	FAB	B1d
106			159- 160	0.3 3	25% EtOAc / 75% hexane	353 (M+H)+	FAB	A5, B1a
107			152- 153	0.3 5	25% EtOAc / 75% hexane	339 (M+H)+	FAB	A5, B1a
108	SMe		246- 247	0.3 0	25% EtOAc / 75% hexane	377 (M+H)+	FAB	B1a
109	SMe		210- 211	0.3 5	25% EtOAc / 75% hexane	345 (M+H)+	CI	B1a
110	SMe		195- 196	0.3 5	25% EtOAc / 75% hexane	314 (M+H)+	FAB	B1a
111	SMe		196- 197	0.4 0	25% EtOAc / 75% hexane	395 (M+H)+	FAB	B1a

Table 3. S-Substituted 2-Methoxy-5-sulfonylphenyl Ureas



Example	R ²	R ³	mp (°C)	TLC R _f	Solvent System	Mass Spec.	Source	Synth. Method
112		F	205- 207			339 (M+H) ⁺	HPLC ES-MS	B1d
113		CHF ₂	195- 196			370 (M ⁺)	EI	B1d
114		CHF ₂		0.46	50% EtOAc / 50% hexane	389 (M+H) ⁺	FAB	B3a
115		CHF ₂		0.21	50% EtOAc / 50% hexane	405 (M+H) ⁺	FAB	B3a
116		CHF ₂		0.23	20% EtOAc / 80% hexane	409 (M+H) ⁺	FAB	B3a
117		CHF ₂		0.40	50% EtOAc / 50% hexane	389 (M+H) ⁺	FAB	B3a
118		CHF ₂		0.53	50% EtOAc / 50% hexane	375 (M+H) ⁺	FAB	B3a
























119		CHF ₂		0.58	50% EtOAc / 50% hexane	389 (M+H) ⁺	FAB	B1c
120		CHF ₂		0.48	50% EtOAc / 50% hexane	389 (M+H) ⁺	FAB	B1d
121		CHF ₂		0.44	50% EtOAc / 50% hexane	393 (M+H) ⁺	FAB	B1c
122		CHF ₂		0.33	5% MeOH / 95% CH ₂ Cl ₂	385 (M+H) ⁺	FAB	B1c
123		CHF ₂				393 (M+H) ⁺	FAB	B1c
124		CHF ₂				409 (M+H) ⁺	FAB	B1c
125		CHF ₂				405 (M+H) ⁺	FAB	B1c
126		CHF ₂		0.56	50% EtOAc / 50% hexane	385 (M+H) ⁺	FAB	B1c
127		CF ₃		0.56	50% EtOAc / 50% hexane	389 (M+H) ⁺	FAB	A3, B1d

Table 4. 3-Substituted-2-naphthyl Ureas



Example	R ¹	R ²	mp (°C)	TLC R _f	Solvent System	Mass Spec.	Source	Synth. Method
128	OMe		171- 172	0.40	25% EtOAc / 75% hexane	307 (M+H) ⁺	FAB	B4
129	OMe		197- 199	0.40	14% EtOAc / 86% hexane	325 (M+H) ⁺	FAB	B4
130	OMe		235- 236	0.45	25% EtOAc / 75% hexane	343 (M+H) ⁺	FAB	A6, B1a
131	OMe		236- 237	0.45	25% EtOAc / 75% hexane	311 (M+H) ⁺	FAB	A6, B1a
132	OMe		209- 211			311 (M+H) ⁺	FAB	A6, B1a
133	OMe		225- 226			321 (M+H) ⁺	FAB	A6, B1a
134	OMe		199- 200			395 (M+H) ⁺	FAB	A6, B1a
135	OMe		227- 228			361 (M+H) ⁺	FAB	A6, B1a

136	OMe		207- 208			327 (M+H)+	FAB	A6, B1a
137	OMe		234- 235			361 (M+H)+	FAB	A6, B1a
138	OMe		228- 229			352 (M+H)+	FAB	A6, B1a
139	OMe		190- 195			323 (M+H)+	FAB	A6, B1a
140	OMe		203- 205			310 (M+H)+	FAB	A6, B1a
141	OMe		209- 210			307 (M+H)+	FAB	A6, B1a
142	OMe		200- 201			323 (M+H)+	FAB	A6, B1a
143	OMe		201- 202			307 (M+H)+	FAB	A6, B1a
144	OMe		216- 218			385 (M+H)+	FAB	A6, B1a
145	OMe		181- 182			361 (M+H)+	FAB	A6, B1a
146	OMe		238- 239	0.25	25% EtOAc / 75% hexane	402 (M+H)+	FAB	B4
147	OMe		199- 200	0.20	25% EtOAc / 75% hexane	384 (M+H)+	FAB	B4
148	OMe		175- 176			321 (M+H)+	FAB	A6, B1a












149	OMe		164- 166			544 (M+H)+	FAB	A6, B1a
150	OMe		206- 209			446 (M+H)+	FAB	A6, B1a
151	OMe		234- 237			410 (M+H)+	FAB	B2a
152	OMe		209- 211	0.40	25% EtOAc / 75% hexane	414 (M+)	EI	B4

Table 5. Misc. Ureas

Example	R ²	mp (°C)	TLC R _f	Solvent System	Mass Spec.	Source	Synth. Method
153		183- 184			327 (M+H) ⁺	FAB	B1d
154		156- 157			312 (M+)	El	B1d
155			0.46	50% EtOAc / 50% hexane	291 (M+H) ⁺	FAB	B1d
156							
157			0.40	50% acetone / 50% CH ₂ Cl ₂	399 (M+H) ⁺	FAB	B5
158		219- 221			336 (M+H) ⁺	FAB	B1d
159		204- 205			305 (M+H) ⁺	FAB	B1d
160		208- 210			302 (M+H) ⁺	FAB	B1d

87

161		226-228			355 (M+H)+	FAB	B1d
162		160-162			328 (M+H)+	FAB	B1a
163			0.85	50% EtOAc / 50% hexane	291 (M+H)+	FAB	B1b
164		225-226	0.60	25% EtOAc / 75% hexane	367 (M+H)+	FAB	A4, B1a
165			0.55	3% MeOH / 97% CH2Cl2	417 (M+H)+	FAB	B6
166		169-171			407 (M+H)+	FAB	B1a
167		158-160		C3	365 (M+H)+	FAB	C3

BIOLOGICAL EXAMPLES

P38 Kinase Assay:

- The *in vitro* inhibitory properties of compounds were determined using a p38 kinase inhibition assay. P38 activity was detected using an *in vitro* kinase assay run in 96-well microtiter plates. Recombinant human p38 (0.5 µg/mL) was mixed with substrate (myelin basic protein, 5 µg/mL) in kinase buffer (25 mM Hepes, 20 mM MgCl₂ and 150 mM NaCl) and compound. One µCi/well of ³²P-labeled ATP (10 µM) was added to a final

volume of 100 μ L. The reaction was run at 32 °C for 30 min. and stopped with a 1M HCl solution. The amount of radioactivity incorporated into the substrate was determined by trapping the labeled substrate onto negatively charged glass fiber filter paper using a 1% phosphoric acid solution and read with a scintillation counter. Negative controls include
5 substrate plus ATP alone.

All compounds exemplified displayed p38 IC₅₀s of between 1 nM and 10 μ M.

LPS Induced TNF α Production in Mice:

10 The *in vivo* inhibitory properties of selected compounds were determined using a murine LPS induced TNF α production *in vivo* model. BALB/c mice (Charles River Breeding Laboratories; Kingston, NY) in groups of ten were treated with either vehicle or compound by the route noted. After one hour, endotoxin (E. coli lipopolysaccharide (LPS) 100 μ g) was administered intraperitoneally (i.p.). After 90 min, animals were
15 euthanized by carbon dioxide asphyxiation and plasma was obtained from individual animals by cardiac puncture into heparinized tubes. The samples were clarified by centrifugation at 12,500 x g for 5 min at 4 °C. The supernatants were decanted to new tubes, which were stored as needed at -20 °C. TNF α levels in sera were measured using a commercial murine TNF ELISA kit (Genzyme).

20

The preceeding examples can be repeated with similar success by substituting the generically of specifically described reactants and/or operating conditions of this invention for those used in the preceeding examples

25 From the foregoing discussion, one skilled in the art can easily ascertain the essential characteristics of this invention and, without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.

5


WHAT IS CLAIMED IS:

1. A method of treating a disease, other than cancer, mediated by p-38,
 10 comprising administering a compound of formula I



wherein

15 A is



B is a substituted or unsubstituted, up to tricyclic aryl or heteroaryl moiety of up to 30 carbon atoms with at least one 6-member aromatic structure containing 0-4 members of the group consisting of nitrogen, oxygen and sulfur, wherein if B is substituted, it is substituted by one or more substituents selected from the group consisting of halogen, up to per-halo, and W_n, wherein n is 0-3 and each W is independently selected from the group consisting of -CN, -CO₂R⁷, -C(O)NR⁷R⁷, -C(O)-R⁷, -NO₂, -OR⁷, -SR⁷, -NR⁷R⁷, -NR⁷C(O)OR⁷, -NR⁷C(O)R⁷, C₁-C₁₀ alkyl, C₁₋₁₀-alkenyl, C₁₋₁₀-alkoxy, C₃-C₁₀ cycloalkyl, C₆-C₁₄ aryl, C₇-C₂₄ alkaryl, C₃-C₁₃ heteroaryl, C₄-C₂₃ alkheteroaryl, substituted C₁-C₁₀ alkyl, substituted C₂₋₁₀-alkenyl, substituted C₁₋₁₀-alkoxy, substituted C₃-C₁₀ cycloalkyl, substituted C₄-C₂₃ alkheteroaryl and Q-Ar;

25

30

wherein if W is a substituted group, it is substituted by one or more substituents independently selected from the group consisting of -CN, -CO₂R⁷, -C(O)R⁷, -C(O)NR⁷R⁷, -OR⁷, -SR⁷, -NR⁷R⁷, NO₂, -NR⁷C(O)R⁷, -NR⁷C(O)OR⁷ and halogen up to per-halo;

5 wherein each R⁷ is independently selected from H, C₁-C₁₀ alkyl, C₂₋₁₀-alkenyl, C₃-C₁₀ cycloalkyl, C₆-C₁₄ aryl, C₃-C₁₃ hetaryl, C₇-C₂₄ alkaryl, C₄-C₂₃ alkheteroaryl, up to per-halosubstituted C₁-C₁₀ alkyl, up to per-halosubstituted C₂₋₁₀-alkenyl, up to per-halosubstituted C₃-C₁₀ cycloalkyl, up to per-halosubstituted C₆-C₁₄ aryl and up to per-halosubstituted C₃-C₁₃ hetaryl,

10 wherein Q is -O-, -S-, -N(R⁷)-, -(CH₂)_m-, -C(O)-, -CH(OH)-, -(CH₂)_mO-, -NR⁷C(O)NR⁷R⁷-, -NR⁷C(O)-, -C(O)NR⁷-, -(CH₂)_mS-, -(CH₂)_mN(R⁷)-, -O(CH₂)_m-, -CHX², -CX²₂-, -S-(CH₂)_m- and -N(R⁷)(CH₂)_m-,


m = 1-3, and X² is halogen; and

Ar is a 5-10 member aromatic structure containing 0-2 members of the group
 15 consisting of nitrogen, oxygen and sulfur, which is unsubstituted or substituted by halogen up to per-halo and optionally substituted by Z_{n1}, wherein n₁ is 0 to 3 and each Z is independently selected from the group consisting of -CN, -CO₂R⁷, -C(O)NR⁷R⁷, -C(O)-NR⁷, -COR⁷, -NO₂, -OR⁷, -SR⁷, -NR⁷R⁷, -NR⁷C(O)OR⁷, -NR⁷C(O)R⁷, C₁-C₁₀ alkyl, C₃-C₁₀ cycloalkyl, C₆-C₁₄ aryl, C₃-C₁₃ hetaryl, C₇-C₂₄ alkaryl, C₄-C₂₃ alkheteroaryl, substituted C₁-C₁₀ alkyl, substituted C₃-C₁₀ cycloalkyl, substituted C₇-C₂₄ alkaryl and substituted C₄-C₂₃ alkheteroaryl; wherein the one or more substituents of Z
 20 is selected from the group consisting of -CN, -CO₂R⁷, -C(O)NR⁷R⁷, -OR⁷, -SR⁷, -NO₂, -NR⁷R⁷, -NR⁷C(O)R⁷, -NR⁷C(O)OR⁷,

25 R³, R⁴, R⁵ are each independently H, C₁₋₁₀-alkyl, optionally substituted by

halogen, up to perhalo, C₁₋₁₀ alkoxy, optionally substituted by halogen, up to perhaloalkoxy, halogen; NO₂ or NH₂;

R⁶ is H, C₁₋₁₀-alkyl, C₁₋₁₀ alkoxy, -NHCOR¹; -NR¹COR¹; NO₂;



one of R^4 , R^5 or R^6 can be $-X-Y$,

or 2 adjacent R^4 - R^6 can together be an aryl or hetaryl ring with 5-12 atoms, optionally substituted by C_{1-10} -alkyl, C_{1-10} alkoxy, C_{3-10} cycloalkyl, C_{2-10} alkenyl, C_{1-10} alkanoyl, C_{6-12} aryl, C_{5-12} hetaryl or C_{6-12} aralkyl;


R^1 is C_{1-10} -alkyl optionally substituted by halogen, up to perhalo;

X is $-\text{CH}_2-$, $-\text{S}-$, $-\text{N}(\text{CH}_3)-$, $-\text{NHC(O)}-$, $-\text{CH}_2-\text{S}-$, $-\text{S}-\text{CH}_2-$, $-\text{C(O)}-$, or $-\text{O}-$; and

X is additionally a single bond where Y is pyridyl;

Y is phenyl, pyridyl, naphthyl, pyridone, pyrazine, benzodioxane, benzopyridine, pyrimidine or benzothiazole, each optionally substituted by


C_{1-10} -alkyl, C_{1-10} -alkoxy, halogen, OH, $-\text{SCH}_3$, or NO_2 or, where Y is phenyl, by



or a pharmaceutically acceptable salt thereof.

15


2. A method according to claim 1, comprising administering a compound of formula Ia



wherein

- 5 R^3 , R^4 , R^5 , and R^6 are each independently H; halogen; C_{1-10} -alkyl optionally substituted by halogen up to perhalo; C_{1-10} -alkoxy optionally substituted by at least one hydroxy group or halogen up to perhalo, C_{6-12} aryl, optionally substituted by C_{1-10} alkoxy or halogen, C_{5-12} hetaryl, optionally substituted by C_{1-10} alkyl, C_{1-10} alkoxy or halogen; NO_2 ; SO_2F ; $-SO_2CH_2X_{3-p}$; $-COOR^1$; $-OR^1CONHR^1$; $-NHCOR^1$; $-SR^1$; NH_2 ; $-N(SO_2R^1)_2$; furyloxy;

10




- 15 2 adjacent R^3-R^6 can together form an aryl or hetaryl ring with 5-12 atoms, optionally substituted by C_{1-10} -alkyl, C_{1-10} -alkoxy, C_{3-10} -cycloalkyl, C_{2-10} -alkenyl, C_{1-10} -alkanoyl, C_{6-12} -aryl, C_{5-12} -hetaryl, C_{6-12} -aralkyl, C_{6-12} -alkaryl, halogen; $-NR^1$; $-NO_2$; $-CF_3$; $-COOR^1$; $-NHCOR^1$; $-CN$; $-CONR^1R^1$; $-SO_2R^2$; $-SOR^2$; $-SR^2$; in which R^1 is H or C_{1-10} -alkyl and R^2 is C_{1-10} -alkyl optionally substituted by halogen, up to perhalo, with $-SO_2$ -
- 20 optionally incorporated in the aryl or hetaryl ring;
- p is 0 or 1;
- one of R^3 , R^4 , R^5 or R^6 can be $-X-Y$,
- with the proviso that if R^3 and R^6 are both H, one of R^4 or R^5 is not H, and R^3-R^6 are as defined in claim 1.

25


3. A method according to claim 2, wherein
- R^3 is H; halogen; C_{1-10} -alkyl optionally substituted by halogen, up to perhalo, NO_2 , $-SO_2F$ or $-SO_2CF_3$;
- R^4 is H, C_{1-10} -alkyl, C_{1-10} -alkoxy, halogen or NO_2 ;
- 30 R^5 is H, C_{1-10} -alkyl optionally substituted by halogen, up to perhalo;
- R^6 is H, hydroxy, C_{1-10} -alkoxy optionally substituted by at least one hydroxy group;

-COOR¹; -OR¹CONHR¹; -NHCOR¹; -SR¹; phenyl optionally substituted by halo or C₁₋₁₀-alkoxy; NH₂; -N(SO₂R¹)₂, furyloxy, thiophene, pyrrole or methyl substituted pyrrole,




5

4. A method according to claim 2, wherein R³ is Cl, F, C₄₋₅-branched alkyl, -SO₂F or -SO₂CF₃; and R⁶ is hydroxy; C₁₋₁₀-alkoxy optionally substituted by at least one hydroxy group; -COOR¹; -OR¹CONHR¹; -NHCOR¹; -SR¹; phenyl optionally substituted by halo or C₁₋₁₀-alkoxy; NH₂; -N(SO₂R¹)₂, furyloxy,



10


5. A compound according to claim 2, wherein R⁴ is C₁₋₁₀-alkyl or halogen; R⁵ is H, C₁₋₁₀-alkyl, halogen, CF₃, halogen, NO₂ or NH₂; and R⁶ is H, C₁₋₁₀-alkyl, halogen, -NHCOCH₃, -N(CH₃)COCH₃, NO₂,



15

6. A method according to claim 2, wherein R⁵ is C₁₋₁₀-alkyl, halogen, CF₃, halogen, NO₂ or NH₂.

7. A method according to claim 2, wherein R⁶ is C₁₋₁₀-alkyl, halogen, -NHCOCH₃, -N(CH₃)COCH₃, NO₂,



8. A method according to claim 4, wherein R³ is t-butyl or CF₃, and R⁶ is -OCH₃.

9. A method according to claim 2, wherein the disease is mediated by a cytokine or protease regulated by p38.

10. A method according to claim 2, wherein the disease is mediated by TNF α , MMP-1, MMP-3, IL-1, IL-6 or IL-8.

11. A method according to claim 2, wherein the disease is an inflammatory or immunomodulatory disease.

12. A method according to claim 2, wherein the disease is osteoarthritis, rheumatoid arthritis, osteoporosis, asthma, septic shock, inflammatory bowel disease, or the result of host-versus-graft reactions.

13. A method according to claim 1, wherein the compound of formula I is
 N-(5-tert-Butyl-2-methoxyphenyl)-N'-(4-phenyloxyphenyl)urea;
 N-(5-tert-Butyl-2-methoxyphenyl)-N'-(4-(4-methoxyphenyloxy)phenyl)urea;
 N-(5-tert-Butyl-2-methoxyphenyl)-N'-(4-(4-pyridinyloxy)phenyl)urea;
 N-(5-tert-Butyl-2-methoxyphenyl)-N'-(4-(4-pyridinylmethyl)phenyl)urea;
 N-(5-tert-Butyl-2-methoxyphenyl)-N'-(4-(4-pyridinylthio)phenyl)urea;
 N-(5-tert-Butyl-2-methoxyphenyl)-N'-(4-(4-(4,7-methano-1H-isoindole-1,3(2H)-

- dionyl)methyl)phenyl)urea;
N-(5-tert-Butyl-2-phenylphenyl)-N'-(2,3-dichlorophenyl)urea;
N-(5-tert-Butyl-2-(3-thienyl)phenyl)-N'-(2,3-dichlorophenyl)urea;
N-(5-tert-Butyl-2-(N-methylaminocarbonyl)methoxyphenyl)-N'-(2,3-
5 dichlorophenyl)urea;
N-(5-tert-Butyl-2-(N-methylaminocarbonyl)methoxyphenyl)-N'-(1-naphthyl)urea;
N-(5-tert-Butyl-2-(N-morpholinocarbonyl)methoxyphenyl)-N'-(2,3-
dichlorophenyl)urea;
N-(5-tert-Butyl-2-(N-morpholinocarbonyl)methoxyphenyl)-N'-(1-naphthyl)urea;
10 N-(5-tert-Butyl-2-methoxyphenyl)-N'-(4-(3-pyridinyl)methylphenyl)urea;
N-(5-tert-Butyl-2-(3-tetrahydrofuranyloxy)phenyl)-N'-(2,3-dichlorophenyl)urea;
N-(5-Trifluoromethyl-2-methoxyphenyl)-N'-(4-methylphenyl)urea;
N-(5-Trifluoromethyl-2-methoxyphenyl)-N'-(4-methyl-2-fluorophenyl)urea;
N-(5-Trifluoromethyl-2-methoxyphenyl)-N'-(4-fluoro-3-chlorophenyl)urea;
15 N-(5-Trifluoromethyl-2-methoxyphenyl)-N'-(4-methyl-3-chlorophenyl)urea;
N-(5-Trifluoromethyl-2-methoxyphenyl)-N'-(4-methyl-3-fluorophenyl)urea;
N-(5-Trifluoromethyl-2-methoxyphenyl)-N'-(2,4-difluorophenyl)urea;
N-(5-Trifluoromethyl-2-methoxyphenyl)-N'-(4-phenyloxy-3,5-
dichlorophenyl)urea;
20 N-(5-Trifluoromethyl-2-methoxyphenyl)-N'-(4-(4-pyridinylmethyl)phenyl)urea;
N-(5-Trifluoromethyl-2-methoxyphenyl)-N'-(4-(4-pyridinylthio)phenyl)urea;
N-(5-Trifluoromethyl-2-methoxyphenyl)-N'-(4-(4-pyridinyloxy)phenyl)urea;
N-(5-Trifluoromethyl-2-methoxyphenyl)-N'-(3-(4-pyridinylthio)phenyl)urea;
N-(5-Trifluoromethyl-2-methoxyphenyl)-N'-(4-(3-(N-methylaminocarbonyl)-
25 phenyloxy)phenyl)-urea;
N-(5-Fluorosulfonyl)-2-methoxyphenyl)-N'-(4-methylphenyl)urea;
N-(5-(Difluoromethanesulfonyl)-2-methoxyphenyl)-N'-(4-methylphenyl)urea;
N-(5-(Difluoromethanesulfonyl)-2-methoxyphenyl)-N'-(4-fluorophenyl)urea;
N-(5-(Difluoromethanesulfonyl)-2-methoxyphenyl)-N'-(4-methyl-2-
30 fluorophenyl)urea;
N-(5-(Difluoromethanesulfonyl)-2-methoxyphenyl)-N'-(4-methyl-3-

fluorophenyl)urea;

N-(5-(Difluoromethanesulfonyl)-2-methoxyphenyl)-N'-(4-methyl-3-chlorophenyl)urea;

5 N-(5-(Difluoromethanesulfonyl)-2-methoxyphenyl)-N'-(4-fluoro-3-chlorophenyl)urea;

N-(5-(Difluoromethanesulfonyl)-2-methoxyphenyl)-N'-(4-fluoro-3-methylphenyl)urea;

N-(5-(Difluoromethanesulfonyl)-2-methoxyphenyl)-N'-(2,3-dimethylphenyl)urea;

N-(5-(Trifluoromethanesulfonyl)-2-methoxyphenyl)-N'-(4-methylphenyl)urea;

10 N-(3-methoxy-2-naphthyl)-N'-(2-fluorophenyl)urea;

N-(3-Methoxy-2-naphthyl)-N'-(4-methylphenyl)urea;

N-(3-Methoxy-2-naphthyl)-N'-(3-fluorophenyl)urea;

N-(3-Methoxy-2-naphthyl)-N'-(4-methyl-3-fluorophenyl)urea;

N-(3-Methoxy-2-naphthyl)-N'-(2,3-dimethylphenyl)urea;

15 N-(3-Methoxy-2-naphthyl)-N'-(1-naphthyl)urea;

N-(3-Methoxy-2-naphthyl)-N'-(4-(4-pyridinylmethyl)phenyl)urea;

N-(3-Methoxy-2-naphthyl)-N'-(4-(4-pyridinylthio)phenyl)urea;


N-(3-Methoxy-2-naphthyl)-N'-(4-(4-methoxyphenyloxy)phenyl)urea; and

20 N-(3-Methoxy-2-naphthyl)-N'-(4-(4-(4,7-methano-1H-isindole-1,3(2H)-dionyl)methyl)phenyl)urea.

N-(2-Hydroxy-4-nitro-5-chlorophenyl)-N'-(phenyl)urea; or

N-(2-Hydroxy-4-nitro-5-chlorophenyl)-N'-(4-(4-pyridinylmethly)phenyl)urea.


14. A compound of formula II



wherein

R^3 , R^4 , R^5 , and R^6 are each independently H; halogen; C_{1-10} -alkyl optionally substituted by halogen up to perhalo; C_{1-10} -alkoxy optionally substituted by at least one hydroxy group; NO_2 ; SO_2F ; $-SO_2CH_2X_{3-6}$; $-COOR^1$; $-OR^1CONHR^1$; $-NHCOR^1$; $-SR^1$; C_{6-12} aryl, optionally substituted by C_{1-10} -alkyl, C_{1-10} alkoxy or halogen, C_{5-12} hetaryl, optionally substituted by C_{1-10} alkyl, C_{1-10} alkoxy or halogen; NH_2 ; $-N(SO_2R^1)_2$; furyloxy;

10




2 adjacent R^3 - R^6 can together form an aryl or hetaryl ring with 5-12 atoms, optionally substituted by C_{1-10} -alkyl, C_{1-10} -alkoxy, C_{3-10} -cycloalkyl, C_{2-10} -alkenyl, C_{1-10} -alkanoyl, C_{6-12} -aryl, C_{5-12} -hetaryl, C_{6-12} -aralkyl, C_{6-12} -alkaryl, halogen; NR^1R^1 , NO_2 ; $-CF_3$; $-COOR^1$; $-NHCOR^1$; $-CN$; $-CONR^1R^1$; $-SO_2R^2$; $-SOR^2$; $-SR^2$; in which R^1 is H or C_{1-10} -alkyl and R^2 is C_{1-10} -alkyl; C_{1-10} -alkoxy, optionally substituted by halogen up to perhaloalkoxy,

15

R^3 , R^4 and R^5 are each independently H, C_{1-10} -alkyl, optionally substituted by halogen, up to perhalo; halogen; NO_2 or NH_2 ;


20

R^6 is H, C_{1-10} -alkyl, halogen, $-NHCOR^1$; $-NR^1COR^1$; NO_2 ;




or 2 adjacent R^4 - R^6 can together be an aryl or hetaryl ring with 5-12 atoms;

- R^1 is C_{1-10} -alkyl;
 n is 0 or 1;
 X is $-CH_2-$, $-S-$, $N(CH_3)-$, $-NHC(O)-$, CH_2-S- , $-S-CH_2-$, $-C(O)-$, or $-O-$; and
 Y is phenyl, pyridyl, naphthyl, pyridone, pyrazine, benzodioxane, benzopyridine,
 5 pyrimidine or benzothiazole, each optionally substituted by
 C_{1-10} -alkyl, C_{1-10} -alkoxy, halogen or NO_2 or, where Y is phenyl, by




or a pharmaceutically acceptable salt thereof,
 with the provisos that

- (a) if R^3 and R^6 are both H, one of R^4 or R^5 is not H,
 10 (c) R^6 is phenyl substituted by halogen, alkoxy substituted by hydroxy,
 $-SO_2CF_3$, $-OR^1CONHR^1$,



furyloxy or $-N(SO_2R^1)_2$; or R^6 is




and

- 15 (c) the compounds have a pK_a greater than 10.


15. A compound according to claim 14, wherein

- R^3 is H, halogen or C_{1-10} -alkyl optionally substituted by halogen, up to perhalo, NO_2 , $-SO_2F$ or $-SO_2CF_3$;
- R^4 is H, C_{1-10} -alkyl, C_{1-10} -alkoxy, halogen or NO_2 ;
- 5 R^5 is H, C_{1-10} -alkyl optionally substituted by halogen, up to perhalo;
- R^6 is H, hydroxy, C_{1-10} -alkoxy optionally substituted by at least one hydroxy group;
- $-COOR^1$; $-OR^1CONHR^1$; $-NHCOR^1$; $-SR^1$; phenyl optionally substituted by halo

or C_{1-10} -alkoxy; NH_2 ; $-N(SO_2R^1)_2$, furyloxy,




- 10 16. A compound according to claim 14, wherein R^3 is Cl, F, C_{4-5} -branched alkyl, $-SO_2F$ or $-SO_2CF_3$; and R^6 is hydroxy; C_{1-10} -alkoxy optionally substituted by at least one hydroxy group; $-COOR^1$; $-OR^1CONHR^1$; $-NHCOR^1$; $-SR^1$; phenyl optionally substituted by halo or C_{1-10} -alkoxy; NH_2 ; $-N(SO_2R^1)_2$, furyloxy,



15

17. A compound according to claim 14, wherein R^4 is C_{1-10} -alkyl or halogen; R^5 is H, C_{1-10} -alkyl, halogen, CF_3 , halogen, NO_2 or NH_2 ; and R^6 is H, C_{1-10} -alkyl, halogen, $-NHCOCH_3$, $-N(CH_3)COCH_3$, NO_2 ,

100



18. A compound according to claim 14, wherein R^3 is t-butyl or CF_3 , and R^6 is $-OCH_3$.

5

19. A compound according to claim 14, which is

N-(5-tert-Butyl-2-(N-methylaminocarbonyl)methoxyphenyl)-N'-(2,3-dichlorophenyl)urea;

N-(5-tert-Butyl-2-(N-methylaminocarbonyl)methoxyphenyl)-N'-(1-naphthyl)urea;

10

N-(5-tert-Butyl-2-(N-morpholinocarbonyl)methoxyphenyl)-N'-(2,3-dichlorophenyl)urea;

N-(5-tert-Butyl-2-(N-morpholinocarbonyl)methoxyphenyl)-N'-(1-naphthyl)urea;

N-(5-tert-Butyl-2-(3-tetrahydrofuranyloxy)phenyl)-N'-(2,3-dichlorophenyl)urea;

N-(5-(Difluoromethanesulfonyl)-2-methoxyphenyl)-N'-(4-methylphenyl)urea;

15

N-(5-(Difluoromethanesulfonyl)-2-methoxyphenyl)-N'-(4-fluorophenyl)urea;

N-(5-(Difluoromethanesulfonyl)-2-methoxyphenyl)-N'-(4-methyl-2-fluorophenyl)urea;

N-(5-(Difluoromethanesulfonyl)-2-methoxyphenyl)-N'-(4-methyl-3-fluorophenyl)urea;

20

N-(5-(Difluoromethanesulfonyl)-2-methoxyphenyl)-N'-(4-methyl-3-chlorophenyl)urea;

N-(5-(Difluoromethanesulfonyl)-2-methoxyphenyl)-N'-(4-fluoro-3-chlorophenyl)urea;


25 N-(5-(Difluoromethanesulfonyl)-2-methoxyphenyl)-N'-(4-fluoro-3-methylphenyl)urea;

N-(5-(Difluoromethanesulfonyl)-2-methoxyphenyl)-N'-(2,3-dimethylphenyl)urea;

or


N-(5-(Trifluoromethanesulfonyl)-2-methoxyphenyl)-N'-(4-methylphenyl)urea.

5 20. A compound of formula II




wherein

R³, R⁴, R⁵, and R⁶ are each independently H; halogen; C₁₋₁₀-alkyl optionally substituted by halogen up to perhalo; C₁₋₁₀-alkoxy optionally substituted by at least one hydroxy group; NO₂; SO₂F; -SO₂CH₂X₃₋₆; -COOR¹; -OR¹CONHR¹; -NHCOR¹; -SR¹; phenyl optionally substituted by halogen or C₁₋₁₀-alkoxy; NH₂; -N(SO₂R¹)₂; furyloxy;



2 adjacent R³-R⁶ can together form an aryl or hetaryl ring with 5-12 atoms, optionally substituted by C₁₋₁₀-alkyl, C₁₋₁₀-alkoxy, C₃₋₁₀-cycloalkyl, C₂₋₁₀-alkenyl, C₁₋₁₀-alkanoyl, C₆₋₁₂-aryl, C₅₋₁₂-hetaryl, C₆₋₁₂-aralkyl, C₆₋₁₂-alkaryl, halogen; -NR¹; -NO₂; -CF₃; -COOR¹; -NHCOR¹; -CN; -CONR¹R¹; -SO₂R²; -SOR²; -SR²; in which R¹ is H or C₁₋₁₀-alkyl and R² is C₁₋₁₀-alkyl;

R³', R⁴' and R⁵' are each independently H, C₁₋₁₀-alkyl, optionally substituted by halogen, up to perhalo; halogen; NO₂ or NH₂;




R^6 is H, C_{1-10} -alkyl, halogen, $-NHCOR^1$; $-NR^1COR^1$; NO_2 ;

R^1 is C_{1-10} -alkyl;

n is 0 or 1;

5 X is $-CH_2-$, $-S-$ or $-O-$; and


Y is phenyl, pyridyl, naphthyl or benzothiazole, each optionally substituted by C_{1-10} -alkyl, C_{1-10} -alkoxy, halogen or NO_2 or, where Y is phenyl, by




or a pharmaceutically acceptable salt thereof

with the provisos that

- 10 (a) if R^3 and R^6 are both H, one of R^4 or R^5 is not H, and
 (b) R^6 is alkoxy substituted by hydroxy, $-SO_2CF_2H$, $-OR^1CONHR^1$,



furyloxy or $-N(SO_2R^1)_2$; or R^6 is



15

21. A pharmaceutical composition comprising a compound of claim 14, and a physiologically acceptable carrier.

22. A pharmaceutical composition comprising a compound of claim 20, and a physiologically acceptable carrier.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/27265**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6) : C07D 273/00, 275/00; A61K 31/17

US CL : 564/52, 53, 54, 55; 514/596, 598

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 564/52, 53, 54, 55; 514/596, 598

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Please See Extra Sheet.

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 3,151,023 A (MARTIN) 29 September 1964, see entire document.	1-22
Y	US 3,200,035 A (MARTIN ET AL.) 10 August 1965, see entire document.	14-22
X	US 3,230,141 (FRICK ET AL.) 18 January 1966, see entire document.	14-22
X	US 4,405,644 A (KABBE ET AL.) 20 September 1983, see entire document.	1-22
Y	GB 0,828,231 A (J.R. GEIGY A.G.) 17 February 1960, see entire document.	14-22

☐ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

09 FEBRUARY 1999

Date of mailing of the international search report

02 MAR 1999

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

FLOYD D. HIGEL aco

Telephone No. (703) 308-1235

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/27265

B. FIELDS SEARCHED

Documentation other than minimum documentation that are included in the fields searched:

Chemical Abstracts

Index Chemicus

Current Abstracts of Chemistry

THIS PAGE BLANK (USPTO)